CN110072540B - 用于tusc2免疫治疗的方法和组合物 - Google Patents
用于tusc2免疫治疗的方法和组合物 Download PDFInfo
- Publication number
- CN110072540B CN110072540B CN201780076886.XA CN201780076886A CN110072540B CN 110072540 B CN110072540 B CN 110072540B CN 201780076886 A CN201780076886 A CN 201780076886A CN 110072540 B CN110072540 B CN 110072540B
- Authority
- CN
- China
- Prior art keywords
- cancer
- tusc2
- antibody
- cells
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101000659267 Homo sapiens Tumor suppressor candidate 2 Proteins 0.000 title claims abstract description 172
- 102100036129 Tumor suppressor candidate 2 Human genes 0.000 title claims abstract description 171
- 239000000203 mixture Substances 0.000 title claims description 79
- 238000000034 method Methods 0.000 title abstract description 76
- 238000009169 immunotherapy Methods 0.000 title description 7
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 203
- 238000011282 treatment Methods 0.000 claims abstract description 127
- 201000011510 cancer Diseases 0.000 claims abstract description 113
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims abstract description 53
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims abstract description 53
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims abstract description 50
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims abstract description 50
- 239000003814 drug Substances 0.000 claims abstract description 38
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 35
- 230000027455 binding Effects 0.000 claims description 87
- 239000002105 nanoparticle Substances 0.000 claims description 77
- 239000002502 liposome Substances 0.000 claims description 75
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 54
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 52
- 150000002632 lipids Chemical class 0.000 claims description 44
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 41
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 30
- 229920001184 polypeptide Polymers 0.000 claims description 27
- 235000012000 cholesterol Nutrition 0.000 claims description 26
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical group [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 claims description 23
- 239000013604 expression vector Substances 0.000 claims description 23
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 20
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 20
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical group FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 20
- 229940124597 therapeutic agent Drugs 0.000 claims description 20
- 210000001519 tissue Anatomy 0.000 claims description 20
- 238000001415 gene therapy Methods 0.000 claims description 19
- 230000001965 increasing effect Effects 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 230000001225 therapeutic effect Effects 0.000 claims description 15
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 12
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 12
- 229940121647 egfr inhibitor Drugs 0.000 claims description 12
- 229960002621 pembrolizumab Drugs 0.000 claims description 12
- 239000013612 plasmid Substances 0.000 claims description 11
- 210000002966 serum Anatomy 0.000 claims description 11
- 102000004127 Cytokines Human genes 0.000 claims description 10
- 108090000695 Cytokines Proteins 0.000 claims description 10
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 229960002584 gefitinib Drugs 0.000 claims description 8
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical group C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 229960003301 nivolumab Drugs 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 238000001356 surgical procedure Methods 0.000 claims description 6
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 5
- 238000011319 anticancer therapy Methods 0.000 claims description 5
- 229960005395 cetuximab Drugs 0.000 claims description 5
- 238000002512 chemotherapy Methods 0.000 claims description 5
- 229960001433 erlotinib Drugs 0.000 claims description 5
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 5
- 239000002078 nanoshell Substances 0.000 claims description 5
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical compound C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 claims description 4
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 229910003472 fullerene Inorganic materials 0.000 claims description 4
- 238000001794 hormone therapy Methods 0.000 claims description 4
- 239000002071 nanotube Substances 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 229960001972 panitumumab Drugs 0.000 claims description 4
- 239000002096 quantum dot Substances 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 239000004054 semiconductor nanocrystal Substances 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims description 3
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 3
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 3
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims description 3
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 238000011394 anticancer treatment Methods 0.000 claims description 3
- 210000003169 central nervous system Anatomy 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 230000002124 endocrine Effects 0.000 claims description 3
- 201000005787 hematologic cancer Diseases 0.000 claims description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 3
- 208000029559 malignant endocrine neoplasm Diseases 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 239000005543 nano-size silicon particle Substances 0.000 claims description 3
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims description 3
- 201000006958 oropharynx cancer Diseases 0.000 claims description 3
- 201000008968 osteosarcoma Diseases 0.000 claims description 3
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 230000000241 respiratory effect Effects 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- NERXPXBELDBEPZ-RMKNXTFCSA-N (e)-n-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC(F)=C1 NERXPXBELDBEPZ-RMKNXTFCSA-N 0.000 claims description 2
- OONFNUWBHFSNBT-HXUWFJFHSA-N AEE788 Chemical compound C1CN(CC)CCN1CC1=CC=C(C=2NC3=NC=NC(N[C@H](C)C=4C=CC=CC=4)=C3C=2)C=C1 OONFNUWBHFSNBT-HXUWFJFHSA-N 0.000 claims description 2
- 108091023037 Aptamer Proteins 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 101001061518 Homo sapiens RNA-binding protein FUS Proteins 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 2
- 238000011122 anti-angiogenic therapy Methods 0.000 claims description 2
- 201000009036 biliary tract cancer Diseases 0.000 claims description 2
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 2
- 229950002826 canertinib Drugs 0.000 claims description 2
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010016629 fibroma Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims description 2
- 229950008001 matuzumab Drugs 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 206010027191 meningioma Diseases 0.000 claims description 2
- 229950008835 neratinib Drugs 0.000 claims description 2
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 claims description 2
- 201000011519 neuroendocrine tumor Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 claims description 2
- WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 claims description 2
- 208000028591 pheochromocytoma Diseases 0.000 claims description 2
- 208000010916 pituitary tumor Diseases 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 206010044285 tracheal cancer Diseases 0.000 claims description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- MUPNITTWEOEDNT-TWMSPMCMSA-N 2,3-bis[[(Z)-octadec-9-enoyl]oxy]propyl-trimethylazanium (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol Chemical compound CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C.CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC MUPNITTWEOEDNT-TWMSPMCMSA-N 0.000 claims 1
- 206010050017 Lung cancer metastatic Diseases 0.000 claims 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 1
- 238000011518 platinum-based chemotherapy Methods 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical group 0.000 claims 1
- 230000005760 tumorsuppression Effects 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 133
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 73
- 108090000623 proteins and genes Proteins 0.000 description 61
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 58
- 230000014509 gene expression Effects 0.000 description 56
- 150000007523 nucleic acids Chemical class 0.000 description 49
- 239000013598 vector Substances 0.000 description 49
- 239000005557 antagonist Substances 0.000 description 47
- 239000003795 chemical substances by application Substances 0.000 description 41
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 38
- -1 B7-4 Proteins 0.000 description 36
- 108020004707 nucleic acids Proteins 0.000 description 35
- 102000039446 nucleic acids Human genes 0.000 description 35
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 31
- 210000000822 natural killer cell Anatomy 0.000 description 30
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 29
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 28
- 229940045513 CTLA4 antagonist Drugs 0.000 description 26
- 108010074708 B7-H1 Antigen Proteins 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 24
- 230000000694 effects Effects 0.000 description 24
- 230000037396 body weight Effects 0.000 description 22
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 19
- 150000003904 phospholipids Chemical class 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- 239000000427 antigen Substances 0.000 description 18
- 108091007433 antigens Proteins 0.000 description 18
- 102000036639 antigens Human genes 0.000 description 18
- 230000006870 function Effects 0.000 description 18
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 17
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 230000004083 survival effect Effects 0.000 description 16
- 239000002246 antineoplastic agent Substances 0.000 description 15
- 239000003112 inhibitor Substances 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 15
- 230000007935 neutral effect Effects 0.000 description 15
- 230000008685 targeting Effects 0.000 description 15
- 238000002648 combination therapy Methods 0.000 description 14
- 239000003550 marker Substances 0.000 description 14
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 14
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 13
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 13
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 13
- 238000000684 flow cytometry Methods 0.000 description 13
- 230000008595 infiltration Effects 0.000 description 13
- 238000001764 infiltration Methods 0.000 description 13
- 239000003446 ligand Substances 0.000 description 13
- 102000005962 receptors Human genes 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 12
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 12
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- 210000004881 tumor cell Anatomy 0.000 description 12
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 description 11
- 108700020796 Oncogene Proteins 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 230000003993 interaction Effects 0.000 description 11
- 230000004614 tumor growth Effects 0.000 description 11
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 10
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 241000700605 Viruses Species 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 210000003719 b-lymphocyte Anatomy 0.000 description 10
- 239000012636 effector Substances 0.000 description 10
- 239000003623 enhancer Substances 0.000 description 10
- 210000002865 immune cell Anatomy 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 229940043355 kinase inhibitor Drugs 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 239000003909 protein kinase inhibitor Substances 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 108010012236 Chemokines Proteins 0.000 description 9
- 229940127089 cytotoxic agent Drugs 0.000 description 9
- 238000003384 imaging method Methods 0.000 description 9
- 238000001802 infusion Methods 0.000 description 9
- 229960005386 ipilimumab Drugs 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 238000007619 statistical method Methods 0.000 description 9
- 238000007920 subcutaneous administration Methods 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 8
- 102000019034 Chemokines Human genes 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000001093 anti-cancer Effects 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 8
- 230000029918 bioluminescence Effects 0.000 description 8
- 238000005415 bioluminescence Methods 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 230000000670 limiting effect Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 230000008488 polyadenylation Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 241000701161 unidentified adenovirus Species 0.000 description 8
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 7
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 7
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 description 7
- 102000017578 LAG3 Human genes 0.000 description 7
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 230000005746 immune checkpoint blockade Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 238000007912 intraperitoneal administration Methods 0.000 description 7
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 230000001177 retroviral effect Effects 0.000 description 7
- 230000019491 signal transduction Effects 0.000 description 7
- 239000013603 viral vector Substances 0.000 description 7
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 6
- 101100315526 Homo sapiens TUSC2 gene Proteins 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 238000012417 linear regression Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 241001430294 unidentified retrovirus Species 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 5
- 102100038078 CD276 antigen Human genes 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000000232 Lipid Bilayer Substances 0.000 description 5
- 108010038807 Oligopeptides Proteins 0.000 description 5
- 102000015636 Oligopeptides Human genes 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 5
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 238000011284 combination treatment Methods 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 230000003463 hyperproliferative effect Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 5
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 5
- 210000003289 regulatory T cell Anatomy 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 4
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 description 4
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 101150105104 Kras gene Proteins 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000002612 dispersion medium Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 229940121354 immunomodulator Drugs 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000011275 oncology therapy Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 239000013600 plasmid vector Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 3
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 3
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 3
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 3
- 102100022338 Integrin alpha-M Human genes 0.000 description 3
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 3
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 3
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 3
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 3
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 3
- 101150030213 Lag3 gene Proteins 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- 241000192656 Nostoc Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108091008611 Protein Kinase B Proteins 0.000 description 3
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 3
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 3
- 102100022869 Ras and EF-hand domain-containing protein Human genes 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 3
- FYAMXEPQQLNQDM-UHFFFAOYSA-N Tris(1-aziridinyl)phosphine oxide Chemical compound C1CN1P(N1CC1)(=O)N1CC1 FYAMXEPQQLNQDM-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229960001686 afatinib Drugs 0.000 description 3
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 3
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 229940125715 antihistaminic agent Drugs 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 229960003005 axitinib Drugs 0.000 description 3
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 3
- 229960000397 bevacizumab Drugs 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 238000001815 biotherapy Methods 0.000 description 3
- 229960003736 bosutinib Drugs 0.000 description 3
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001720 carbohydrates Chemical group 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000022534 cell killing Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229960004630 chlorambucil Drugs 0.000 description 3
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 230000000139 costimulatory effect Effects 0.000 description 3
- 229960005061 crizotinib Drugs 0.000 description 3
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 3
- 238000011498 curative surgery Methods 0.000 description 3
- 239000000824 cytostatic agent Substances 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 229960002448 dasatinib Drugs 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229960002411 imatinib Drugs 0.000 description 3
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000002601 intratumoral effect Effects 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229960004891 lapatinib Drugs 0.000 description 3
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 238000007639 printing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 108010014186 ras Proteins Proteins 0.000 description 3
- 102000016914 ras Proteins Human genes 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 102200006539 rs121913529 Human genes 0.000 description 3
- HXCHCVDVKSCDHU-PJKCJEBCSA-N s-[(2r,3s,4s,6s)-6-[[(2r,3s,4s,5r,6r)-5-[(2s,4s,5s)-5-(ethylamino)-4-methoxyoxan-2-yl]oxy-4-hydroxy-6-[[(2s,5z,9r,13e)-9-hydroxy-12-(methoxycarbonylamino)-13-[2-(methyltrisulfanyl)ethylidene]-11-oxo-2-bicyclo[7.3.1]trideca-1(12),5-dien-3,7-diynyl]oxy]-2-m Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-PJKCJEBCSA-N 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 229950007217 tremelimumab Drugs 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- CGMTUJFWROPELF-YPAAEMCBSA-N (3E,5S)-5-[(2S)-butan-2-yl]-3-(1-hydroxyethylidene)pyrrolidine-2,4-dione Chemical compound CC[C@H](C)[C@@H]1NC(=O)\C(=C(/C)O)C1=O CGMTUJFWROPELF-YPAAEMCBSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- RFVFQQWKPSOBED-PSXMRANNSA-N 1-myristoyl-2-palmitoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCC RFVFQQWKPSOBED-PSXMRANNSA-N 0.000 description 2
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 2
- MEOVPKDOYAIVHZ-UHFFFAOYSA-N 2-chloro-1-(1-methylpyrrol-2-yl)ethanol Chemical compound CN1C=CC=C1C(O)CCl MEOVPKDOYAIVHZ-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 102000007471 Adenosine A2A receptor Human genes 0.000 description 2
- 108010085277 Adenosine A2A receptor Proteins 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CEIZFXOZIQNICU-UHFFFAOYSA-N Alternaria alternata Crofton-weed toxin Natural products CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000212384 Bifora Species 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 235000003351 Brassica cretica Nutrition 0.000 description 2
- 235000003343 Brassica rupestris Nutrition 0.000 description 2
- 241000219193 Brassicaceae Species 0.000 description 2
- MBABCNBNDNGODA-LTGLSHGVSA-N Bullatacin Natural products O=C1C(C[C@H](O)CCCCCCCCCC[C@@H](O)[C@@H]2O[C@@H]([C@@H]3O[C@H]([C@@H](O)CCCCCCCCCC)CC3)CC2)=C[C@H](C)O1 MBABCNBNDNGODA-LTGLSHGVSA-N 0.000 description 2
- 101710185679 CD276 antigen Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- 108010013198 Daptomycin Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 101100342473 Drosophila melanogaster Raf gene Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 101150086923 ERB1 gene Proteins 0.000 description 2
- 102000050554 Eph Family Receptors Human genes 0.000 description 2
- 108091008815 Eph receptors Proteins 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 102100029951 Estrogen receptor beta Human genes 0.000 description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
- 229920002430 Fibre-reinforced plastic Polymers 0.000 description 2
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 2
- KGPGFQWBCSZGEL-ZDUSSCGKSA-N GSK690693 Chemical compound C=12N(CC)C(C=3C(=NON=3)N)=NC2=C(C#CC(C)(C)O)N=CC=1OC[C@H]1CCCNC1 KGPGFQWBCSZGEL-ZDUSSCGKSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 2
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 2
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 description 2
- 101100510618 Homo sapiens LAG3 gene Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108020005350 Initiator Codon Proteins 0.000 description 2
- 102100025305 Integrin alpha-2 Human genes 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 108091082332 JAK family Proteins 0.000 description 2
- 108010043610 KIR Receptors Proteins 0.000 description 2
- 102000002698 KIR Receptors Human genes 0.000 description 2
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- ULDXWLCXEDXJGE-UHFFFAOYSA-N MK-2206 Chemical compound C=1C=C(C=2C(=CC=3C=4N(C(NN=4)=O)C=CC=3N=2)C=2C=CC=CC=2)C=CC=1C1(N)CCC1 ULDXWLCXEDXJGE-UHFFFAOYSA-N 0.000 description 2
- 229940124640 MK-2206 Drugs 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 2
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 2
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 2
- 238000011495 NanoString analysis Methods 0.000 description 2
- 229940121678 PD-L2 antagonist Drugs 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 102000038030 PI3Ks Human genes 0.000 description 2
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 2
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 2
- 238000011530 RNeasy Mini Kit Methods 0.000 description 2
- 101100523543 Rattus norvegicus Raf1 gene Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 101150001535 SRC gene Proteins 0.000 description 2
- 229920001800 Shellac Polymers 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 108700026226 TATA Box Proteins 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- CGMTUJFWROPELF-UHFFFAOYSA-N Tenuazonic acid Natural products CCC(C)C1NC(=O)C(=C(C)/O)C1=O CGMTUJFWROPELF-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 101100523549 Xenopus laevis raf1 gene Proteins 0.000 description 2
- 101150037250 Zhx2 gene Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 229960000473 altretamine Drugs 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940124650 anti-cancer therapies Drugs 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 229940045713 antineoplastic alkylating drug ethylene imines Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 230000005975 antitumor immune response Effects 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 108010006025 bovine growth hormone Proteins 0.000 description 2
- 229960005520 bryostatin Drugs 0.000 description 2
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 2
- MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 description 2
- 108700002839 cactinomycin Proteins 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229930195731 calicheamicin Natural products 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 229960000590 celecoxib Drugs 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000009134 cell regulation Effects 0.000 description 2
- 230000004700 cellular uptake Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000012050 conventional carrier Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 2
- 229960005484 daptomycin Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229960000616 diflunisal Drugs 0.000 description 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 229960000520 diphenhydramine Drugs 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 229950009791 durvalumab Drugs 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 229940056913 eftilagimod alfa Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960005167 everolimus Drugs 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 239000011151 fibre-reinforced plastic Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- 210000003976 gap junction Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 102000048362 human PDCD1 Human genes 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 239000012642 immune effector Substances 0.000 description 2
- 230000007938 immune gene expression Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 2
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 108091008042 inhibitory receptors Proteins 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960003784 lenvatinib Drugs 0.000 description 2
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- QTFKTBRIGWJQQL-UHFFFAOYSA-N meturedepa Chemical compound C1C(C)(C)N1P(=O)(NC(=O)OCC)N1CC1(C)C QTFKTBRIGWJQQL-UHFFFAOYSA-N 0.000 description 2
- 229950009847 meturedepa Drugs 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229960003775 miltefosine Drugs 0.000 description 2
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 235000010460 mustard Nutrition 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 229960005419 nitrogen Drugs 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229960000639 pazopanib Drugs 0.000 description 2
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 2
- 229960003407 pegaptanib Drugs 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 2
- 229960000624 procarbazine Drugs 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 229960003876 ranibizumab Drugs 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- MBABCNBNDNGODA-WPZDJQSSSA-N rolliniastatin 1 Natural products O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@H]1[C@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@@H](O)CC=2C(O[C@@H](C)C=2)=O)CC1 MBABCNBNDNGODA-WPZDJQSSSA-N 0.000 description 2
- 102200006531 rs121913529 Human genes 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 150000003873 salicylate salts Chemical class 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000004208 shellac Substances 0.000 description 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
- 229940113147 shellac Drugs 0.000 description 2
- 235000013874 shellac Nutrition 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229960001967 tacrolimus Drugs 0.000 description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- URLYINUFLXOMHP-HTVVRFAVSA-N tcn-p Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O URLYINUFLXOMHP-HTVVRFAVSA-N 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 230000005026 transcription initiation Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 2
- 229950001353 tretamine Drugs 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- SPDZFJLQFWSJGA-UHFFFAOYSA-N uredepa Chemical compound C1CN1P(=O)(NC(=O)OCC)N1CC1 SPDZFJLQFWSJGA-UHFFFAOYSA-N 0.000 description 2
- 229950006929 uredepa Drugs 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- YWTBGJGMTBHQTM-IBGZPJMESA-N (2S)-1-(1H-indol-3-yl)-3-[[5-(3-methyl-2H-indazol-5-yl)-3-pyridinyl]oxy]-2-propanamine Chemical compound C1=CC=C2C(C[C@H](N)COC=3C=NC=C(C=3)C3=CC=C4NN=C(C4=C3)C)=CNC2=C1 YWTBGJGMTBHQTM-IBGZPJMESA-N 0.000 description 1
- VXAGJYXIHQKJIP-REOHCLBHSA-N (2S)-2-azido-3-hydroxypropanoic acid Chemical compound [N+](=[N-])=N[C@@H](CO)C(=O)O VXAGJYXIHQKJIP-REOHCLBHSA-N 0.000 description 1
- AJACDNCVEGIBNA-KQYNXXCUSA-N (2r,3r,4s,5r)-2-(6-amino-2-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C12=NC(OC)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O AJACDNCVEGIBNA-KQYNXXCUSA-N 0.000 description 1
- ABXYOVCSAGTJAC-JGWLITMVSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanethial Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=S ABXYOVCSAGTJAC-JGWLITMVSA-N 0.000 description 1
- KYBXNPIASYUWLN-WUCPZUCCSA-N (2s)-5-hydroxypyrrolidine-2-carboxylic acid Chemical compound OC1CC[C@@H](C(O)=O)N1 KYBXNPIASYUWLN-WUCPZUCCSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- INAUWOVKEZHHDM-PEDBPRJASA-N (7s,9s)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7-[(2r,4s,5s,6s)-5-hydroxy-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1 INAUWOVKEZHHDM-PEDBPRJASA-N 0.000 description 1
- RCFNNLSZHVHCEK-IMHLAKCZSA-N (7s,9s)-7-(4-amino-6-methyloxan-2-yl)oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound [Cl-].O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)C1CC([NH3+])CC(C)O1 RCFNNLSZHVHCEK-IMHLAKCZSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- LZLVZIFMYXDKCN-QJWFYWCHSA-N 1,2-di-O-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC LZLVZIFMYXDKCN-QJWFYWCHSA-N 0.000 description 1
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- IJFVSSZAOYLHEE-SSEXGKCCSA-N 1,2-dilauroyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCC IJFVSSZAOYLHEE-SSEXGKCCSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- AJACDNCVEGIBNA-UHFFFAOYSA-N 2-Methoxyadenosine Natural products C12=NC(OC)=NC(N)=C2N=CN1C1OC(CO)C(O)C1O AJACDNCVEGIBNA-UHFFFAOYSA-N 0.000 description 1
- 125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- LGEXGKUJMFHVSY-UHFFFAOYSA-N 2-n,4-n,6-n-trimethyl-1,3,5-triazine-2,4,6-triamine Chemical compound CNC1=NC(NC)=NC(NC)=N1 LGEXGKUJMFHVSY-UHFFFAOYSA-N 0.000 description 1
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical class CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
- YIMDLWDNDGKDTJ-QLKYHASDSA-N 3'-deamino-3'-(3-cyanomorpholin-4-yl)doxorubicin Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1C#N YIMDLWDNDGKDTJ-QLKYHASDSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 101150039504 6 gene Proteins 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- 239000013607 AAV vector Substances 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 229940126638 Akt inhibitor Drugs 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 101710144268 B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102000005738 B7 Antigens Human genes 0.000 description 1
- 108010045634 B7 Antigens Proteins 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 229940125565 BMS-986016 Drugs 0.000 description 1
- 229940125431 BRAF inhibitor Drugs 0.000 description 1
- 101150017888 Bcl2 gene Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- MHIOPLSAMAVLPQ-SSEXGKCCSA-N CCCCCCCCCCCCCCCCCCCCCCO[C@H](CO)COP([O-])(OCC[N+](C)(C)C)=O Chemical compound CCCCCCCCCCCCCCCCCCCCCCO[C@H](CO)COP([O-])(OCC[N+](C)(C)C)=O MHIOPLSAMAVLPQ-SSEXGKCCSA-N 0.000 description 1
- 108010017158 CCR7 Receptors Proteins 0.000 description 1
- 102000004428 CCR7 Receptors Human genes 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 101100080277 Caenorhabditis elegans ncr-1 gene Proteins 0.000 description 1
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 description 1
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
- 244000132059 Carica parviflora Species 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 241000509579 Draco Species 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101150000195 EGR3 gene Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101710113436 GTPase KRas Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 101150046249 Havcr2 gene Proteins 0.000 description 1
- 241000893313 Helochara delta Species 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101001010910 Homo sapiens Estrogen receptor beta Proteins 0.000 description 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000945371 Homo sapiens Killer cell immunoglobulin-like receptor 2DL2 Proteins 0.000 description 1
- 101000945333 Homo sapiens Killer cell immunoglobulin-like receptor 2DL3 Proteins 0.000 description 1
- 101000945343 Homo sapiens Killer cell immunoglobulin-like receptor 2DS3 Proteins 0.000 description 1
- 101000945342 Homo sapiens Killer cell immunoglobulin-like receptor 2DS4 Proteins 0.000 description 1
- 101001034314 Homo sapiens Lactadherin Proteins 0.000 description 1
- 101100407307 Homo sapiens PDCD1LG2 gene Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 1
- 101000823778 Homo sapiens Y-box-binding protein 2 Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000037978 Immune checkpoint receptors Human genes 0.000 description 1
- 108091008028 Immune checkpoint receptors Proteins 0.000 description 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
- 102100039340 Interleukin-18 receptor 1 Human genes 0.000 description 1
- 101710184759 Interleukin-18 receptor 1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102100033599 Killer cell immunoglobulin-like receptor 2DL2 Human genes 0.000 description 1
- 102100033634 Killer cell immunoglobulin-like receptor 2DL3 Human genes 0.000 description 1
- 102100033625 Killer cell immunoglobulin-like receptor 2DS3 Human genes 0.000 description 1
- 102100033624 Killer cell immunoglobulin-like receptor 2DS4 Human genes 0.000 description 1
- ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- CZQHHVNHHHRRDU-UHFFFAOYSA-N LY294002 Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1C1=CC=CC=C1 CZQHHVNHHHRRDU-UHFFFAOYSA-N 0.000 description 1
- 102100039648 Lactadherin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102100032241 Lactotransferrin Human genes 0.000 description 1
- 108010000851 Laminin Receptors Proteins 0.000 description 1
- 102000002297 Laminin Receptors Human genes 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 102100020872 Leucyl-cystinyl aminopeptidase Human genes 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 239000002616 MRI contrast agent Substances 0.000 description 1
- 229930126263 Maytansine Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 206010073148 Multiple endocrine neoplasia type 2A Diseases 0.000 description 1
- 101100381525 Mus musculus Bcl6 gene Proteins 0.000 description 1
- 101100013967 Mus musculus Gata3 gene Proteins 0.000 description 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 241001028048 Nicola Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 229930187135 Olivomycin Natural products 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 229940123751 PD-L1 antagonist Drugs 0.000 description 1
- QIUASFSNWYMDFS-NILGECQDSA-N PX-866 Chemical compound CC(=O)O[C@@H]1C[C@]2(C)C(=O)CC[C@H]2C2=C1[C@@]1(C)[C@@H](COC)OC(=O)\C(=C\N(CC=C)CC=C)C1=C(O)C2=O QIUASFSNWYMDFS-NILGECQDSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 101710114878 Phospholipase A-2-activating protein Proteins 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 102100022427 Plasmalemma vesicle-associated protein Human genes 0.000 description 1
- 101710193105 Plasmalemma vesicle-associated protein Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 102100028469 RNA-binding protein FUS Human genes 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 241001068295 Replication defective viruses Species 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
- 241000713311 Simian immunodeficiency virus Species 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- BXFOFFBJRFZBQZ-QYWOHJEZSA-N T-2 toxin Chemical compound C([C@@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@H]1[C@]3(COC(C)=O)C[C@@H](C(=C1)C)OC(=O)CC(C)C)O2 BXFOFFBJRFZBQZ-QYWOHJEZSA-N 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 238000012338 Therapeutic targeting Methods 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000405217 Viola <butterfly> Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 101710145727 Viral Fc-gamma receptor-like protein UL119 Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 238000001790 Welch's t-test Methods 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- CWRILEGKIAOYKP-SSDOTTSWSA-M [(2r)-3-acetyloxy-2-hydroxypropyl] 2-aminoethyl phosphate Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCCN CWRILEGKIAOYKP-SSDOTTSWSA-M 0.000 description 1
- JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- 238000010317 ablation therapy Methods 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- OFLXLNCGODUUOT-UHFFFAOYSA-N acetohydrazide Chemical compound C\C(O)=N\N OFLXLNCGODUUOT-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229930188522 aclacinomycin Natural products 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- QNHQEUFMIKRNTB-UHFFFAOYSA-N aesculetin Natural products C1CC(=O)OC2=C1C=C(O)C(O)=C2 QNHQEUFMIKRNTB-UHFFFAOYSA-N 0.000 description 1
- GUAFOGOEJLSQBT-UHFFFAOYSA-N aesculetin dimethyl ether Natural products C1=CC(=O)OC2=C1C=C(OC)C(OC)=C2 GUAFOGOEJLSQBT-UHFFFAOYSA-N 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000010441 alabaster Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229950010817 alvocidib Drugs 0.000 description 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- XKMRRTOUMJRJIA-UHFFFAOYSA-N ammonia nh3 Chemical compound N.N XKMRRTOUMJRJIA-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 150000008209 arabinosides Chemical class 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
- 229960005207 auranofin Drugs 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 150000001541 aziridines Chemical class 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- MBABCNBNDNGODA-LUVUIASKSA-N bullatacin Chemical compound O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@@H]1[C@@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@@H](O)CC=2C(O[C@@H](C)C=2)=O)CC1 MBABCNBNDNGODA-LUVUIASKSA-N 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 229950009908 cactinomycin Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000011116 calcium hydroxide Nutrition 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- 229930188550 carminomycin Natural products 0.000 description 1
- XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 229950001725 carubicin Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- ITVPBBDAZKBMRP-UHFFFAOYSA-N chloro-dioxido-oxo-$l^{5}-phosphane;hydron Chemical compound OP(O)(Cl)=O ITVPBBDAZKBMRP-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- RMXVHZFHSKRNJN-UHFFFAOYSA-N chlorourea Chemical compound NC(=O)NCl RMXVHZFHSKRNJN-UHFFFAOYSA-N 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000002247 constant time method Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002681 cryosurgery Methods 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- DMSZORWOGDLWGN-UHFFFAOYSA-N ctk1a3526 Chemical compound NP(N)(N)=O DMSZORWOGDLWGN-UHFFFAOYSA-N 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000021040 cytoplasmic transport Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- LHCZDUCPSRJDJT-UHFFFAOYSA-N dilauroyl phosphatidylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCC LHCZDUCPSRJDJT-UHFFFAOYSA-N 0.000 description 1
- BPHQZTVXXXJVHI-UHFFFAOYSA-N dimyristoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-UHFFFAOYSA-N 0.000 description 1
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 1
- 229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 description 1
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
- 229930188854 dolastatin Natural products 0.000 description 1
- 239000011363 dried mixture Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- ILEDWLMCKZNDJK-UHFFFAOYSA-N esculetin Chemical compound C1=CC(=O)OC2=C1C=C(O)C(O)=C2 ILEDWLMCKZNDJK-UHFFFAOYSA-N 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229950005309 fostamatinib Drugs 0.000 description 1
- GKDRMWXFWHEQQT-UHFFFAOYSA-N fostamatinib Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(NC=3N=C4N(COP(O)(O)=O)C(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=C1 GKDRMWXFWHEQQT-UHFFFAOYSA-N 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000008303 genetic mechanism Effects 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002343 gold Chemical class 0.000 description 1
- 229940015045 gold sodium thiomalate Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 102000053464 human BTLA Human genes 0.000 description 1
- 102000048770 human CD276 Human genes 0.000 description 1
- 102000043321 human CTLA4 Human genes 0.000 description 1
- 102000049109 human HAVCR2 Human genes 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960003445 idelalisib Drugs 0.000 description 1
- YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 description 1
- 208000036260 idiopathic disease Diseases 0.000 description 1
- 229940126546 immune checkpoint molecule Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000035990 intercellular signaling Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 102000008625 interleukin-18 receptor activity proteins Human genes 0.000 description 1
- 108040002014 interleukin-18 receptor activity proteins Proteins 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 235000014413 iron hydroxide Nutrition 0.000 description 1
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical class [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 1
- 229950011263 lirilumab Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007762 localization of cell Effects 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- YROQEQPFUCPDCP-UHFFFAOYSA-N losoxantrone Chemical compound OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO YROQEQPFUCPDCP-UHFFFAOYSA-N 0.000 description 1
- 229950008745 losoxantrone Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960002868 mechlorethamine hydrochloride Drugs 0.000 description 1
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 229960003539 mitoguazone Drugs 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 101150005437 mucA gene Proteins 0.000 description 1
- 101150069935 mucB gene Proteins 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- BRZOTEHEMOQUOY-UHFFFAOYSA-N n-[bis(aziridin-1-yl)phosphoryl]benzamide Chemical compound C=1C=CC=CC=1C(=O)NP(=O)(N1CC1)N1CC1 BRZOTEHEMOQUOY-UHFFFAOYSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 description 1
- 229940100656 nasal solution Drugs 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- CZDBNBLGZNWKMC-MWQNXGTOSA-N olivomycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1)O[C@H]1O[C@@H](C)[C@H](O)[C@@H](OC2O[C@@H](C)[C@H](O)[C@@H](O)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@H](O)[C@H](OC)[C@H](C)O1 CZDBNBLGZNWKMC-MWQNXGTOSA-N 0.000 description 1
- 229950005848 olivomycin Drugs 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940124624 oral corticosteroid Drugs 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 229940046781 other immunosuppressants in atc Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000011499 palliative surgery Methods 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- BLFWHYXWBKKRHI-JYBILGDPSA-N plap Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H](N)CCC(O)=O BLFWHYXWBKKRHI-JYBILGDPSA-N 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 229920002946 poly[2-(methacryloxy)ethyl phosphorylcholine] polymer Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
- 239000003197 protein kinase B inhibitor Substances 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000013608 rAAV vector Substances 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 125000005630 sialyl group Chemical group 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 101150104943 slc44a4 gene Proteins 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- AGHLUVOCTHWMJV-UHFFFAOYSA-J sodium;gold(3+);2-sulfanylbutanedioate Chemical compound [Na+].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O AGHLUVOCTHWMJV-UHFFFAOYSA-J 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 208000034223 susceptibility to 2 systemic lupus erythematosus Diseases 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 101150047061 tag-72 gene Proteins 0.000 description 1
- ATFXVNUWQOXRRU-UHFFFAOYSA-N taminadenant Chemical compound BrC=1C(N)=NC(N2N=CC=C2)=NC=1N1C=CC=N1 ATFXVNUWQOXRRU-UHFFFAOYSA-N 0.000 description 1
- 238000010863 targeted diagnosis Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229930013292 trichothecene Natural products 0.000 description 1
- 150000003327 trichothecene derivatives Chemical class 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229960001670 trilostane Drugs 0.000 description 1
- KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 1
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 description 1
- 229960001128 triprolidine Drugs 0.000 description 1
- FQCQGOZEWWPOKI-UHFFFAOYSA-K trisalicylate-choline Chemical compound [Mg+2].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O FQCQGOZEWWPOKI-UHFFFAOYSA-K 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000029584 urinary system neoplasm Diseases 0.000 description 1
- 208000037964 urogenital cancer Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- LLYYNOVSVPBRGV-MVNKZKPCSA-N valnemulin Chemical compound CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@@]23CC[C@@H](C)[C@]1(C)[C@@H]2C(=O)CC3 LLYYNOVSVPBRGV-MVNKZKPCSA-N 0.000 description 1
- 229950008166 valnemulin Drugs 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
治疗患有癌症之对象的方法,其包括施用与免疫检查点抑制剂结合的肿瘤抑制治疗,例如TUSC2治疗。还提供了用于癌症治疗的药盒和药剂。
Description
本申请要求于2016年10月12日提交的美国临时专利申请No.62/407,329的权益,其全部内容通过引用并入本文。
背景技术
1.技术领域
本文提供的本发明实施方案一般性地涉及分子生物学、免疫学和癌症治疗领域。
2.相关领域的描述
随着肿瘤发生的分子和遗传机制得到更好的阐明,癌症治疗的重点已从组织转向遗传水平(Bishop,1991)。癌基因和肿瘤抑制基因(tumor suppressor gene,TSG)这两大类基因的突变在肿瘤发生过程中起着核心作用。TSG似乎需要纯合缺失或突变以失活,并且TSG表达的恢复在人肿瘤中是可行的(Lowe等,2004;Roth,2006)。肺癌细胞系和原发性肺肿瘤中3p21.3区域的纯合缺失导致从该区域鉴定出多个具有肿瘤抑制活性的基因(Lerman等,2000)。这些缺失已导致了靶向抗癌治疗的发展。然而,尚不清楚如何提高这样的治疗的效力。
发明概述
在第一个实施方案中,提供了治疗患有癌症之对象的方法,其包括施用与免疫检查点抑制剂结合的肿瘤抑制治疗(例如,TUSC2治疗)。因此,提供了用于治疗患有癌症之对象的方法,其中该对象正在用至少一种免疫检查点抑制剂进行治疗(或先前施用了至少一种免疫检查点抑制剂),该方法包括向所述对象施用肿瘤抑制治疗(例如TUSC2治疗)。例如,用TUSC2治疗进行治疗的对象可以是在施用TUSC2治疗之前少于1小时、6小时、12小时、1天、3天、一周或两周施用免疫检查点抑制剂的对象。本文中使用的TUSC2治疗可以是在癌细胞中提供或导致TUSC2多肽表达的任何类型的治疗(参见,例如,美国专利No.7,902,441,通过引用并入本文)。例如,TUSC2治疗可包括将TUSC2多肽或TUSC2表达载体递送至癌细胞。例如,治疗可通过纳米颗粒递送,或在核酸表达载体的情况下通过使用病毒载体递送。
在某些实施方案中,提供了用于治疗患有癌症之对象的方法,其包括向对象施用与至少一种免疫检查点抑制剂结合的TUSC2治疗。例如,TUSC2治疗可以在至少一种免疫检查点抑制剂之前、之后或基本上与之同时施用。因此,在一些实施方案中,提供了用于治疗癌症的组合物,其包含治疗有效量的TUSC2治疗剂和免疫检查点抑制剂。
在一些方面,至少一种检查点抑制剂选自CTLA-4、PD-1、PD-L1、PD-L2、LAG-3、BTLA、B7H3、B7H4、TIM3、KIR或A2aR的抑制剂。在某些方面,至少一种免疫检查点抑制剂是人程序性细胞死亡1(PD-1)轴结合拮抗剂。在一些方面,PD-1轴结合拮抗剂选自PD-1结合拮抗剂、PDL1结合拮抗剂和PDL2结合拮抗剂。在某些方面,PD-1轴结合拮抗剂是PD-1结合拮抗剂。在一些方面,PD-1结合拮抗剂抑制PD-1与PDL1和/或PDL2的结合。在一些特定方面,PD-1结合拮抗剂是单克隆抗体或其抗原结合片段。在一些特定方面,PD-1结合拮抗剂是纳武单抗(nivolumab)、派姆单抗(pembrolizumab)、匹地利珠单抗(pidillizumab)、AMP-514、REGN2810、CT-011、BMS 936559、MPDL328OA或AMP-224。在一些方面,至少一种免疫检查点抑制剂是抗CTLA-4抗体。在一些特定方面,抗CTLA-4抗体是曲美木单抗(tremelimumab)、/>或伊匹单抗(ipilimumab)。在某些方面,至少一种免疫检查点抑制剂是抗杀伤细胞免疫球蛋白样受体(killer-cell immunoglobulin-likereceptor,KIR)抗体。在一些方面,抗KIR抗体是利鲁单抗(lirilumab)。在某些方面,对象已经或正在施用多于一种免疫检查点抑制剂,例如抗PD1抗体和抗CTLA4抗体。
在某些实施方案中,施用TUSC2治疗包括施用TUSC2表达载体,例如编码TUSC2的DNA质粒。根据本文提供的实施方案使用的表达载体一般性地包含用于表达TUSC2编码序列的控制元件。例如,载体可包含对于在目的癌细胞中表达有效的启动子和增强子元件。在某些方面,例如,TUSC2表达由CMV启动子或其重组形式(例如在美国专利公开No.20070092968中描述的CMV启动子构建体,通过引用并入本文)提供。在某些实施方案中,本文提供的载体包含经修饰的CMV启动子。在某些实施方案中,本文提供的载体包含mini-CMV启动子。可包含另外的表达控制元件,例如内含子、药物响应元件、RNA稳定化或去稳定化序列、细胞定位信号、多腺苷酸化信号序列和/或优化的翻译起始密码子。质粒DNA载体还可包含有助于促进DNA产生的序列,例如,细菌复制起点和/或抗药性标志物。在某些特定方面,TUSC2表达载体是pLJ143/KGB2/FUS1质粒。
用于将表达载体递送至细胞(例如,体内递送)的方法是本领域公知的,并且包括但不限于纳米颗粒(例如,脂质体纳米颗粒)、脂质缀合物和病毒载体。在某些方面,TUSC2表达载体在纳米颗粒中施用,例如N-[1-(2,3-二油酰氧基)丙基]-N,N,N-三甲基氯化铵(DOTAP):胆固醇脂质体纳米颗粒。技术人员将认识到可以调节脂质体的多种特性以优化载体递送。例如,可以将脂质体调节至具有一定的尺寸范围和/或特定比的DNA与脂质;DNA与胆固醇;或脂质与胆固醇。例如,在DOTAP:胆固醇脂质体的情况下,DOTAP:胆固醇比可以限定为约1.5∶1至1∶1.5,例如约10∶9。在另外的方面,TUSC2表达载体在脂质体纳米颗粒中提供,其中纳米颗粒的平均颗粒尺寸为约50至约500nm(例如,200至500nm)。在另外的方面,TUSC2-纳米颗粒制剂可以通过它们的光密度(optical density,OD)来限定,例如OD400为约0.65至0.95。
在另外的实施方案中,TUSC2治疗可包括施用TUSC2多肽。用于施用TUSC2多肽的方法已在例如美国公开No.20060251726和20090023207中进行描述,其通过引用并入本文。可修饰TUSC2多肽以提高其活性和/或进入癌细胞的能力。例如,可以用脂质部分(例如,经肉豆蔻酰化的)修饰多肽。在某些方面,TUSC2作为纳米颗粒(例如,基于脂质的纳米颗粒)提供,例如超顺磁性纳米颗粒、纳米壳、半导体纳米晶体、量子点、基于聚合物的纳米颗粒、基于硅的纳米颗粒、基于二氧化硅的纳米颗粒、基于金属的纳米颗粒、富勒烯或纳米管。
根据本文提供的实施方案,TUSC2治疗和/或免疫检查点抑制剂通常配制在可药用载体中。根据实施方案的治疗可通过以下途径进行递送:例如静脉内、皮内、动脉内、腹膜内、病灶内、颅内、关节内、前列腺内、胸膜内、气管内、鼻内、玻璃体内、阴道内、直肠内、表面、瘤内、肌内、腹膜内、皮下、结膜下、囊内(intravesicularlly)、经黏膜、心包内、脐内(intraumbilically)、眼内、经口、经表面、局部、通过吸入(例如,气雾剂吸入)、通过注射或通过输注,并且递送途径可以取决于待治疗癌症的类型。例如,与DOTAP:胆固醇脂质体复合的TUSC2表达载体可以通过静脉内输注施用。在某些具体方面,TUSC2治疗以约0.01mg/kg至约0.10mg/kg的剂量,例如约0.02、0.03、0.04、0.05、0.06、0.07、0.08、0.09或0.10mg/kg的剂量静脉内施用。在另外的方面,TUSC2治疗可以施用两次或更多次(例如,3、4、5、6、7、8、9或10次)。这样的治疗的剂量之间的时间可以变化,并且可包括但不限于在剂量之间约1、2或3天,约1、2或3周,或者1个月或更长时间。
在另一个实施方案中,提供了用于治疗患有癌症之对象的方法,其包括向对象施用与至少一种免疫检查点抑制剂结合和/或与一种或更多种抗炎剂结合的TUSC2治疗。例如,可在TUSC2治疗之前、之后或期间施用抗炎剂。在另一个方面,施用多于一种抗炎剂,例如施用抗组胺药和皮质类固醇。因此,在某些特定方面,与TUSC2治疗结合使用的抗炎药是苯海拉明和/或地塞米松。
在另外的实施方案中,本文提供的方法还包括施用另外的抗癌治疗。另外的抗癌治疗可以是但不限于手术治疗、化学治疗(例如,施用蛋白激酶抑制剂或EGFR靶向治疗)、放射治疗、冷冻治疗、高热治疗、光治疗、放射消融治疗、激素治疗、免疫治疗、小分子治疗、受体激酶抑制剂治疗、抗血管生成治疗、细胞因子治疗或生物治疗例如单克隆抗体、siRNA、反义寡核苷酸、核酶或基因治疗。不受限制地,生物治疗可以是基因治疗,例如肿瘤抑制基因治疗、细胞死亡蛋白基因治疗、细胞周期调节基因治疗、细胞因子基因治疗、毒素基因治疗、免疫基因治疗、自杀基因治疗、前药基因治疗、抗细胞增殖基因治疗、酶基因治疗或抗血管生成因子基因治疗。
因此,在另一个实施方案中,本文提供了用于治疗患有癌症之对象的组合物、治疗和方法,其包括向对象施用与免疫检查点抑制剂和另外的抗癌剂(例如化学治疗剂)结合的TUSC2治疗(例如,TUSC2多肽或TUSC2表达载体)。例如,化学治疗剂可以是蛋白激酶抑制剂,如Src或Akt激酶抑制剂。在一些方面,化学治疗剂是表皮生长因子受体(epidermal growthfactor receptor,EGFR)抑制剂。
因此,在某些实施方案中,提供了用于治疗患有癌症之对象的方法,其包括向对象施用与至少一种免疫检查点抑制剂和任选地蛋白激酶抑制剂结合的TUSC2治疗。例如,TUSC2治疗和/或免疫检查点抑制剂可以在蛋白激酶抑制剂之前、之后或基本上与之同时施用。因此,在一些实施方案中,提供了用于治疗癌症的组合物,其包含治疗有效量的TUSC2治疗剂、免疫检查点抑制剂和蛋白激酶抑制剂。根据一些实施方案使用的蛋白激酶抑制剂包括但不限于EGFR、VEGFR、AKT、Erb1、Erb2、ErbB、Syk、Bcr-Ab1、JAK、Src、GSK-3、PI3K、Ras、Raf、MAPK、MAPKK、mTOR、c-Kit、eph受体或BRAF抑制剂。例如,蛋白激酶抑制剂可以是阿法替尼(Afatinib)、阿西替尼(Axitinib)、贝伐单抗(Bevacizumab)、博舒替尼(Bosutinib)、西妥昔单抗(Cetuximab)、克唑替尼(Crizotinib)、达沙替尼(Dasatinib)、厄洛替尼(Erlotinib)、福他替尼(Fostamatinib)、吉非替尼(Gefitinib)、伊马替尼(Imatinib)、拉帕替尼(Lapatinib)、乐伐替尼(Lenvatinib)、木利替尼(Mubritinib)、尼罗替尼(Nilotinib)、帕尼单抗(Panitumumab)、帕唑帕尼(Pazopanib)、哌加他尼(Pegaptanib)、雷珠单抗(Ranibizumab)、鲁索替尼(Ruxolitinib)、塞卡替尼(Saracatinib)、索拉非尼(Sorafenib)、舒尼替尼(Sunitinib)、曲妥珠单抗(Trastuzumab)、凡德他尼(Vandetanib)、AP23451、威罗菲尼(Vemurafenib)、CAL101、PX-866、LY294002、雷帕霉素、替西罗莫司(temsirolimus)、依维莫司(everolimus)、地磷莫司(ridaforolimus)、阿沃西地(Alvocidib)、金雀异黄素(Genistein)、司美替尼(Selumetinib)、AZD-6244、瓦他拉尼(Vatalanib)、P1446A-05、AG-024322、ZD1839、P276-00、GW572016,或其混合物。在某些方面,蛋白激酶抑制剂是AKT抑制剂(例如,MK-2206、GSK690693、A-443654、VQD-002、米替福新(Miltefosine)或哌立福新(Perifosine))。
根据一些实施方案使用的EGFR靶向治疗包括但不限于EGFR/ErbB1/HER、ErbB2/Neu/HER2、ErbB3/HER3和/或ErbB4/HER4的抑制剂。广泛的这样的抑制剂是已知的并且包括但不限于针对受体具有活性的酪氨酸激酶抑制剂和EGFR结合抗体或适配体。例如,EGFR抑制剂可以是吉非替尼、厄洛替尼、西妥昔单抗、马妥珠单抗(matuzumab)、帕尼单抗、AEE788;CI-1033、HKI-272、HKI-357或EKB-569。在某些实施方案中,本文提供的组合物和治疗全身或局部施用。在一个实施方案中,本文提供的组合物和治疗全身施用。在某些方面,EGFR抑制剂在TUSC2治疗之前、之后或基本上与之同时向患者施用。例如,治疗可共同施用,例如通过静脉内输注共同施用。在某些实施方案中,TUSC2和EGFR抑制剂可以以有效治疗癌症的任意量施用。在某些实施方案中,本文提供的组合物、治疗和方法包括以比单独施用的任一组合物更低的剂量施用TUSC2和EGFR抑制剂。在某些实施方案中,所述组合物、治疗和方法包括以降低副作用的较低剂量施用TUSC2和EGFR抑制剂。在某些实施方案中,组合物、治疗和方法包括以比单独施用的任一组合物所提供的叠加、协作或协同效应更有效的剂量施用TUSC2治疗、免疫检查点抑制剂和EGFR抑制剂。在某些方面,用这样的治疗进行治疗的癌症可以是本文所述的任何癌症,例如肺癌(例如,非小细胞肺癌)。在某些优选的方面,用组合治疗进行治疗的癌症是表达EGFR的癌症。在某些实施方案中,表达EGFR的癌症包含至少1%、5%、10%、15%、20%、25%、30%、35%、40%、45%、50%、55%、65%、70%、75%、80%、85%、90%、95%、96%、97%,98%或99%的表达EGFR的肿瘤细胞。
在另一个实施方案中,本文提供了用于治疗患有癌症之对象的方法,其中先前确定癌症表达EGFR,该方法包括向对象施用与免疫检查点抑制剂和EGFR抑制剂结合的TUSC2治疗。在某些实施方案中,本文提供了用于治疗患有癌症之对象的方法,其包括以下步骤:确定癌症是否表达EGFR,并且向对象施用TUSC2、免疫检查点抑制剂和EGFR抑制剂。用于评估癌症的EGFR表达状态的方法已在例如美国专利公开No.20110052570中进行描述,通过引用并入本文。在某些方面,表达EGFR的癌症可以是表达突变EGFR的癌症,例如表达具有L858R和/或T790M突变的EGFR的癌症。在某些实施方案中,向患有表达EGFR的癌症的患者施用本文所提供的组合物和治疗,所述癌症包含至少1%、5%、10%、15%、20%、25%、30%、35%、40%、45%、50%、55%、65%、70%、75%、80%、85%、90%、95%、96%、97%、98%或99%的表达EGFR的肿瘤细胞。在另外的方面,治疗对象患有先前确定表达EGFR的癌症,并且其中至少10%的癌症细胞是凋亡的。在某些实施方案中,本文提供的方法还包括确定是否至少10%、15%、20%、25%、30%、35%、40%、45%、50%、55%、65%、70%、75%、80%、85%、90%、95%、96%、97%、98%或99%的表达EGFR的癌细胞是凋亡的。
在某些实施方案中,用于治疗或评估的癌症可表现为肿瘤,例如原发性或转移性肿瘤。癌症可能是早期癌症,或可能是转移性或晚期癌症。在某些方面,癌症是口腔癌、口咽癌、鼻咽癌、呼吸系统癌(respiratory cancer)、泌尿生殖系统癌(urogenital cancer)、胃肠癌、中枢或周围神经系统组织癌(central or peripheral nervous system tissuecancer)、内分泌或神经内分泌癌(endocrine or neuroendocrine cancer)、造血癌(hematopoietic cancer)、胶质瘤、肉瘤、上皮癌(carcinoma)、淋巴瘤、黑素瘤、纤维瘤、脑膜瘤、脑癌、口咽癌、鼻咽癌、肾癌、胆道癌(biliary cancer)、前列腺癌、嗜铬细胞瘤、胰岛细胞癌、利-弗劳梅尼瘤(Li-Fraumeni tumor)、甲状腺癌、甲状旁腺癌、垂体瘤、肾上腺瘤、成骨肉瘤肿瘤(osteogenic sarcoma tumor)、I型和II型多发性神经内分泌肿瘤、乳腺癌、肺癌(例如,非小细胞肺癌(non-small cell lung cancer,NSCLC)或小细胞肺癌(smallcell lung cancer,SCLC))、头颈癌(head&neck cancer)、前列腺癌、食管癌、气管癌、皮肤癌脑癌、肝癌、膀胱癌、胃癌、胰腺癌、卵巢癌、子宫癌、宫颈癌、睾丸癌、结肠癌、直肠癌或皮肤癌。在另外的方面,癌症可被限定为对一种或更多种抗癌治疗具有抗性的癌症,例如抗化学治疗性癌症。例如,癌症可以是对基于铂的化学治疗剂(例如顺铂)具有抗性的癌症。
在上述实施方案的一些方面,施用TUSC2治疗和至少一种免疫检查点抑制剂导致肿瘤中NK和/或CD8+T细胞密度提高。在一些具体方面,CD8+T细胞密度提高至少3倍,例如4、5、6、7、8、9或10倍。在一些方面,施用TUSC2治疗和至少一种免疫检查点抑制剂导致了CcL3、CcL4、CcL21a和/或CcL19血清水平。
在另外的实施方案中,本文提供了包含TUSC2治疗剂和至少一种免疫检查点抑制剂的药盒(kit)。例如,在一些方面,本文提供的药盒包含TUSC2治疗剂、至少一种免疫检查点抑制剂和用于测试对象以确定其对TUSC2治疗剂和/或免疫检查点抑制剂的应答的药剂。例如,用于测试对象以确定其对TUSC2治疗剂的应答的药剂可以是用于确定对象的癌细胞中的凋亡水平的药剂。在另外的方面,药盒还包含一种或更多种抗炎剂或激酶抑制剂。在另外的方面,药盒可包含一种或更多种另外的组件,包括但不限于可药用稀释剂、注射器、输注袋、输注线和/或一套使用该药盒的说明书。
预期本文中所述的任何方法或组合物可以针对本文中所述的任何其他方法或组合物来实施。同样,在用于治疗对象的方法的背景下讨论的本发明实施方案的方面同样适用于预测对象中的应答的方法,并且反之亦然。
当在权利要求和/或说明书中与术语“包括/包含”结合使用时,未用数量词限定的名词可意指“一个/种”,但它也与“一个或更多个/种”、“至少一个/种”或“一个/种或多于一个/种”的含义一致。
如本文中使用的,就指定组分而言的“基本上不含”在本文中用于意指没有指定组分被有目的地配制成组合物和/或仅作为污染物或以痕量存在。因此,由组合物的任何非预期的污染导致的特定组分的总量远低于0.01%。最优选的是其中用标准分析方法不能检测到特定组分之量的组合物。
如本文在说明书和权利要求书中所用的,没有数量词修饰的名词可以意指一个/种或更多个/种。如本文在说明书和权利要求书中所用的,当与词语“包含/包括”结合使用时,没有数量词修饰的名词可以意指一个/种或多于一个/种。如本文中使用的,在说明书和权利要求书中,“另一”或“另一个”可意指至少两个或更多个。
如本文在说明书和权利要求中所使用的,术语“约”用于表示这样的值,其包括装置、用于确定该值之方法的固有的误差变化,或者存在于研究对象之间的变化。
从以下详细描述中,本发明的其他目标、特征和优点将变得明显。然而,应当理解,虽然详细描述和具体实例指示了本发明的某些实施方案,但是其仅以举例说明的方式给出,因为根据该详细描述,本发明的精神和范围内的各种改变和修改对于本领域技术人员将变得明显。
附图简述
以下附图构成本说明书的一部分,并且被包括在内以进一步说明本发明的某些方面。通过结合本文中给出的具体实施方案的详细描述来参考这些附图中的一个或更多个可以更好地理解本发明。
图1A至1E:通过TUSC2和抗PD1组合治疗发现对CMT167皮下模型的增强的抗肿瘤活性。(A)示出了肿瘤接种、治疗方案和剂量、用于免疫细胞分析的血液和脾收集和用于免疫组织化学的肿瘤收获,以及RNA分离的顺序治疗策略。(B)通过流式细胞术确定CMT167-luc细胞上的PD-L1的表面表达水平。(C)、(D)基于通过IVIS 200的小动物成像产生的肿瘤体积和生物发光强度确定四个不同治疗组(N=10只小鼠/组)的肿瘤生长曲线。对照组用装载有空(无TUSC2基因)载体的纳米囊泡进行治疗。TUSC2+PD1治疗导致了对肿瘤生长的最强的抑制作用,随后是TUSC2、PD1和对照。(E)具有通过IVIS 200成像采集的生物发光信号的来自每个治疗组的荷瘤小鼠的代表性图像。该数据为四个独立实验的代表。使用SAS中的PROCMIXED程序中的CONTRAST语句来比较治疗组之间的成像强度。使用9.4版本的SAS和8.04版本的S-Plus以执行所有分析的计算。除非另有说明,否则统计以P<0.05的显著性水平显示。*,P<0.05;**,P<0.01;***,P<0.001。
图2A至2F:组合的TUSC2和抗PD1上调了自然杀伤和细胞毒性T细胞并下调了调节细胞。TUSC2+抗PD1治疗改变了外周血和脾中的免疫细胞群。对照组用装载有空(无TUSC2基因)载体的纳米囊泡进行治疗。(A)TUSC2对无肿瘤小鼠的NK、T细胞和B细胞的影响。将n=3只小鼠/组的合并的样品用于流式细胞术分析。基于外源TUSC2表达确定TUSC2纳米囊泡的体内摄取。静脉内注射TUSC2纳米囊泡之后24小时,从脾中分选出4种不同的免疫群体(T细胞、B细胞、NK细胞和Lin阴性细胞),并进行RT-PCR以确定TUSC2的表达。(B)肿瘤植入第2周时TUSC2和TUSC2+抗PD1治疗对自然杀伤(NK)细胞、T细胞和B细胞的影响。(C)TUSC2治疗改变了MDSC状态。使用以下设门策略确定单核细胞和粒细胞MDSC;CD45+>CD3->MHCII低>CD11b+>Gr-1+。CD11b+Gr-l高被认为是粒细胞MDSC,而CD11b+Gr-1低被认为是单核细胞MDSC。数据显示为平均百分比±SD,n=5。*,P<0.05;**,P<0.01;***P<0.001。(D)治疗对外周血和脾细胞中Treg的影响。T淋巴细胞群的CD4+CD25+双阳性被认为是Treg。数据显示为平均百分比±SD,n=5,**,P<0.01;***P<0.001。(E)PD1、CTLA4和Tim-3在T淋巴细胞上的表面表达。数据显示为CD3+PD1+/CLTA4+/Tim-3+的平均百分比±SD,n=5;*,P<0.05;**,P<0.01;***P<0.001。(F)TUSC2和抗PD1的治疗效果显示为外周血白细胞中的NK/MDSC细胞以及CD8T效应细胞/Treg细胞的比。数据显示为平均值±SD,n=5,流式数据的统计分析通过SAS中的PROC GENMOD程序中的一般线性回归模型和CONTRAST语句完成。*,P<0.05;**,P<0.01;***P<0.001。
图3A至3C:与抗PD1组合的TUSC2提高了NK和CD8T细胞的浸润并阻碍了MDSC和Treg的浸润。(A)用装载有空(无TUSC2基因)载体的纳米囊泡(对照)、TUSC2纳米囊泡、抗PD1和TUSC2+抗PDl治疗皮下肿瘤。经福尔马林固定的切除的肿瘤用以下免疫染色:针对活化的NK细胞的抗CD8和抗NKp46;针对MDSC的抗Gr-1、针对Treg的抗Foxp3。使用Vectra自动成像系统拍摄高分辨率图像(20X),其中对25%的肿瘤区域进行成像。对N=5个肿瘤切片/组进行成像。通过InForm软件分析每个治疗组大约100个图像以用于H评分。使用一般线性回归模型对治疗组之间的H评分进行统计分析。使用复合对称协方差结构来解释数据的小鼠间的变异性和重复测量性质。使用SAS中PROC MIXED程序中的ESTIMATE语句以比较每对治疗组之间的H评分。*,P<0.05;**,P<0.01;***P<0.001。(B)从来自治疗组的新切除的肿瘤(n=3个肿瘤/治疗组)中提取RNA,并通过NanoString技术确定趋化因子的基因表达。将数据归一化并通过nCounter分析软件分析表达的倍数变化。将倍数变化与对照样品进行比较。条显示平均倍数变化(n=3)。(C)显示了由TUSC2治疗诱导的血清中的CCL4和CCL5趋化因子的水平。根据方法中描述的方案用TUSC2治疗皮下荷瘤小鼠。治疗之后10天收集血清并进行luminex多路复用ELISA。使用线性回归模型以比较治疗组之间的趋化因子。使用SAS中PROCMIXED程序中的ESTIMATE语句来比较每对治疗组之间的趋化因子。使用9.4版本的SAS和8.04版本的S-Plus以执行所有分析的计算。数据;平均值±SD;N=3;***,P<0.001。
图4A至4F:TUSC2的抗肿瘤活性对产生Th1介导的免疫应答的自然杀伤细胞的依赖性。细胞因子IL-15和IL-18与自然杀伤细胞调节有关。(A)NK细胞的耗竭消除了治疗效力和抗肿瘤免疫应答。肿瘤生物发光强度图显示了来自在NK耗竭和非耗竭小鼠中用TUSC2和组合治疗的肿瘤的信号。每3天注射NK1.1抗体进行5次以耗竭NK细胞。对照组用装载有空(无TUSC2基因)载体的纳米囊泡治疗。*,P<0.05;**,P<0.01。(B)肿瘤强度图中显示的受CD8T细胞耗竭的影响的TUSC2+抗PD1治疗的抗肿瘤活性(n=5只小鼠/组)。(C)治疗之后10天,通过1uminex测定确定NK耗竭和未耗竭小鼠中的IFN-γ和IL-4细胞因子的血清水平,并且条显示为IFN-γ(Th1)和IL-4(Th2)的比。数据显示为平均值±SD,n=3。*,P<0.05;**,P<0.01;***,P<0.001;****,P<0.0001。(D)在NK耗竭和未耗竭小鼠中在治疗之后IL-18和IL-15细胞因子水平的变化。使用Luminex测定测量血清细胞因子。数据显示为平均值pg/ml±SD,n=3。*,P<0.05;**,P<0.01;***,P<0.001;****,P<0.0001。(E)与对照相比,来自用TUSC2治疗的小鼠的分选的NK细胞中IL-15Ra和IL-18R1的倍数表达。数据显示为平均值±SD,n=3;通过多重t检验确定*P<0.05;**,P<0.01。(F)用于比较IL-15Ra和IL-18R1的倍数变化mRNA表达的用TUSC2和TUSC2+PD1治疗的肿瘤的NanoString分析。
图5A至5I:组合的TUSC2和抗PD1治疗显著提高了KRAS-突变体肺转移小鼠模型中的存活并将自然杀伤细胞募集至荷瘤的肺。(A)344SQ-luc细胞用于该实验性转移模型,其具有KrasG12D等位基因并且具有Trp53R172HΔG等位基因的敲入。通过流式细胞术确定PD-L1表达水平,并与CMT167-luc细胞进行比较。(B)示意性显示了检查点阻断(抗PD1和抗CTLA4)和TUSC2的顺序治疗。(C)治疗之后以Kaplan Meier曲线显示存活。静脉内注射344SQ细胞,并且用单独的TUSC2和检查点阻断或其组合治疗小鼠(以组显示)。对照组用装载有空(无TUSC2基因)载体的纳米囊泡治疗并记录存活(n=10只小鼠/组)。使用单变量Cox模型进行统计分析,以比较治疗组之间的总体存活。在TUSC2+PD1组(左)中观察到最高的存活百分比,随后是TUSC2、PD1和对照。类似地,在TUSC2+PD1+CTL4组(右)中观察到最高的存活百分比,随后是TUSC2、PD1+CTLA4和对照。(D)通过IVIS 200拍摄的荷瘤小鼠的生物发光图像显示出肿瘤细胞的肺特异性定植。治疗组之间显示信号强度水平。显示了三个独立实验的代表。(E)显示肿瘤植入之后两周的肿瘤结节状态的经解剖的肺部图像。(F)(G)(H)&(I)根据方法中描述的方案从来自不同组的转移肺制备单一细胞,并通过流式细胞术确定CD49b+NK细胞、CD4+CD25+Treg、Gr-1+MDSC和PD-L-1以及PD-L2(+)ve白细胞浸润。基于每克肿瘤组织对数据进行归一化。NK细胞根据CD45+CD3-CD19-设门;如下对MDSC进行设门:CD45+>CD3->MHCII低>CDl1b+>GR-1+。PD+CT表明抗PD1和抗CTLA4治疗。数据显示为细胞/克组织±SD,n=5。*,P<0.05;**,P<0.01;***,P<0.001。使用SAS中的PROC GENMOD程序中的CONTRAST语句来比较流式数据用于统计分析。
图6A至6F:组合的TUSC2和抗PD1治疗改变了肿瘤微环境中的免疫基因表达谱。对来自四个治疗组(空载体纳米囊泡、TUSC2、抗PD1和组合)的12个样品(n=3/治疗组)进行776个基因的NanoString泛癌免疫组(panel)的基因表达分析。在用于将基因谱进行量化和统计分析之前,将nCounter系统生成的数据归一化。使用阳性对照、持家基因和阴性对照以针对样品制备变化、背景噪音和RNA含量变化进行调节。使用线性模型来评价总体治疗效果,并且使用对照物以进行目的成对比较。使用β-均匀混合物(beta-uniform mixture,BUM)模型对得到的p值进行建模,以确定错误发现率(false discovery rate,FDR)截止值并识别显著差异表达的基因。(A)热图显示治疗组间的总体显著基因。在治疗下33个基因发生显著变化。(B)TUSC2+抗PD1和抗PD1之间的成对比较鉴定了另一组13个基因。火山图显示了通过治疗上调和下调的基因的分离。在统计学上显著的基因以颜色显示。(C)与单一药剂治疗相比,已知用于抗肿瘤免疫应答的所选基因在组合治疗组中高度上调至少2倍。(D)、(E)和(F)显示与对照相比,分别通过TUSC2、抗PD1和组合治疗的CD8、INF-γ和转录因子(Tbx21、Gata3)表达的倍数变化。此处显示的所有基因表达数据均由NanoString技术生成。
图7:显示外周血白细胞和脾细胞的设门策略以确定用于多色流式细胞术测定的免疫亚群。
图8A至8B:NK耗竭抗体(NK1.1)对其他免疫细胞的影响。根据方法中描述的方案,腹膜内注射NK1.1进行5次。最终注射之后3天评价NK耗竭的效率。通过流式细胞术分析脾细胞的T细胞、B细胞和NK细胞。(A)用于分析的设门策略。(B)将N=3只小鼠样品合并在一起用于进行CD45、CD3、CD19、CD49b抗体染色,并且以条形图显示每个群体的百分比。代表性散点图显示NK耗竭的效率。
图9:CD8T耗竭对其他免疫细胞的影响。根据方法中描述的方案,进行腹膜内注射CD8T细胞耗竭抗体5次。最终注射之后3天评价NK耗竭的效率。通过流式细胞术分析脾细胞的T细胞、B细胞和NK细胞。代表性散点图显示在不影响其他细胞的情况下CD8T细胞耗竭的效率。
图10:肿瘤微环境中的NanoString基因表达分析。PD1和TUSC2+PD1组合治疗之间的成对比较显示出13个显著改变的基因。列出了所有13个基因的P值和倍数变化。使用线性模型来评价总体治疗效果,并且使用对照物以进行目的成对比较。使用β-均匀混合物(BUM)模型对得到的p值进行建模,以确定错误发现率(FDR)截止值并识别显著差异表达的基因。
具体实施方式
癌症的发展涉及控制正常细胞生长的许多细胞通路的失调。健康细胞表达许多肿瘤抑制基因,它们充当分子守门者并阻止不受控制的细胞分裂。因此,癌细胞发展中的重要步骤是破坏肿瘤抑制信号传导通路。鉴于此,癌症治疗的一种有希望的途径涉及在癌细胞中表达肿瘤抑制基因以恢复正常的细胞生长控制。然而,迄今为止还不知道何种类型可能起到提高肿瘤抑制治疗(例如TUSC2治疗)效力的作用。
本专利申请中的研究首次证明,TUSC2治疗在与免疫检查点抑制剂结合施用时特别有效。免疫检查点抑制剂(例如抗PD1治疗)通过提高个体自身的免疫细胞而起作用以抑制肿瘤的生长。相反,用肿瘤抑制剂(例如TUSC2治疗)对肿瘤进行治疗性治疗意味着使癌细胞的转化表型逆转。由于后一种治疗(如果有的话)会使肿瘤细胞“转化更少”并且可能免疫原性更低,因此试图将TUSC2治疗与免疫检查点抑制剂一起使用在之前是与直觉相悖的。尽管如此,在此提出的研究证明,当免疫检查点抑制剂(例如,抗PD1和/或CTLA4)与TUSC2治疗组合时,其抗肿瘤效力实际上显著提高(参见例如,图1)。
具体地,在本研究中,抗PD1在作为具有不同PDL-1表达水平的肺腺癌的同基因小鼠模型的两种Kras突变体(G12V和G12D)中显示出在抑制肿瘤生长和延长存活中的有限效力。然而,当与TUSC2基因恢复相结合时,对肿瘤消退和存活的影响要大得多。TUSC2改变了先天性和适应性免疫细胞群二者。这可以通过循环性NK和CD8+T细胞的显著增加以及源自骨髓的抑制细胞(MDCS)、调节性T细胞(Tregs)、B细胞、T细胞检查点受体PD1和T淋巴细胞相关蛋白4(CTLA-4)以及包含黏蛋白结构域-3(TIM-3)的减少来证明。通过TUSC2-抗PD1组合诱导了肿瘤浸润性NK和CD8+T细胞的密度。体内耗竭NK或CD8+T细胞分别完全和部分地减轻了组合的效力,表明虽然CD8+T细胞可能有助于TUSC2增强的对抗PD1的敏感性,但这种协同作用需要NK细胞。在TUSC2恢复之后,干扰素下(IFNγ)、白介素15和18(IL15和IL18)的细胞因子水平显著提高,这还通过双重检查点阻断、抗PD1+抗CTLA-4增强存活。基因表达谱分析显示通过TUSC2-抗PD1组合治疗改变了肿瘤微环境。这些数据表明这种新型组合治疗可能是治疗Kras突变体肺腺癌的潜在策略。
因此,本文详述的方法首次提供了通过结合使用免疫检查点抑制剂和肿瘤抑制剂(例如TUSC2治疗)来治疗癌症的有效方法。
I.免疫检查点阻断
术语“免疫检查点”是指免疫系统的组分,所述免疫系统向其组分提供抑制信号以调节免疫反应。已知的免疫检查点蛋白包括CTLA-4、PD-1及其配体PD-L1和PD-L2以及另外的LAG-3、BTLA、B7H3、B7H4、TIM3、KIR。涉及LAG3、BTLA、B7H3、B7H4、TIM3和KIR的通路在本领域中被认为构成类似于CTLA-4和PD-1依赖性通路的免疫检查点通路(参见例如Pardoll,2012,Nature Rev Cancer 12:252-264;Mellman等,2011,Nature 480:480-489)。
术语“PD-1轴结合拮抗剂”是指这样的分子:其抑制PD-1轴结合配偶体(bindingpartner)与其一个或更多个结合配偶体相互作用,以去除由PD-1信号传导轴上的信号传导导致的T细胞功能障碍,结果是恢复或增强T细胞功能(例如,增殖、细胞因子产生、靶细胞杀伤)。术语“PD-1轴”是指PD-1免疫检查点的任何组分(例如,PD-1、PD;-L1和PD-L2)。如本文中使用的,PD-1轴结合拮抗剂包括PD-1结合拮抗剂、PD-L1结合拮抗剂和PD-L2结合拮抗剂。
术语“PD-1结合拮抗剂”是指这样的分子,其降低、阻断、抑制、消除或干扰由PD-1与其一个或更多个结合配偶体(例如PD-L1和/或PD-L2)的相互作用导致的信号转导。PD-1结合拮抗剂可以是抑制PD-1与其一个或更多个结合配偶体的结合的分子。在一个特定方面,PD-1结合拮抗剂抑制PD-1与PD-L1和/或PD-L2的结合。例如,PD-1结合拮抗剂包括抗PD-1抗体、其抗原结合片段、免疫黏附蛋白(immunoadhesin)、融合蛋白、寡肽,以及降低、阻断、抑制、消除或干扰由PD-1与PD-L1和/或PD-L2的相互作用导致的信号转导的其他分子。示例性的PD-1结合拮抗剂是抗PD-1抗体。例如,PD-1结合拮抗剂是MDX-1106(纳武单抗)、MK-3475(派姆单抗)、CT-011(匹地利珠单抗)或AMP-224。
术语“PD-L1结合拮抗剂”是指这样的分子,其降低、阻断、抑制、消除或干扰由PD-L1与其一个或更多个结合配偶体(例如PD-1或B7-1)相互作用导致的信号转导。例如,PD-L1结合拮抗剂是抑制PD-L1与其结合配偶体的结合的分子。在一个特定方面,PD-L1结合拮抗剂抑制PD-L1与PD-1和/或B7-1的结合。PD-L1结合拮抗剂可包括抗PD-L1抗体、其抗原结合片段、免疫黏附蛋白、融合蛋白、寡肽,以及降低、阻断、抑制、消除或干扰由PD-L1与其一个或更多个结合配偶体(例如PD-1或B7-1)的相互作用导致的信号转导的其他分子。例如,PD-L1结合拮抗剂降低了通过PD-L1的负共刺激信号介导的信号传导,所述负共刺激信号由或通过T淋巴细胞上表达的细胞表面蛋白介导,从而使功能障碍的T细胞的功能障碍降低(例如增强对抗原识别的效应物应答)。在一个实例中,PD-L1结合拮抗剂是抗PD-L1抗体。抗PD-L1抗体可以是YW243.55.S70、MDX-1105、MPDL3280A或MEDI4736。
术语“PD-L2结合拮抗剂”是指这样的分子,其降低、阻断、抑制、消除或干扰由PD-L2与其一个或更多个结合配偶体(例如PD-1)的相互作用导致的信号转导。PD-L2结合拮抗剂可以是抑制PD-L2与其一个或更多个结合配偶体的结合的分子。例如,PD-L2结合拮抗剂抑制PD-L2与PD-1的结合,例如PD-L2拮抗剂,包括抗PD-L2抗体、其抗原结合片段、免疫黏附蛋白、融合蛋白、寡肽,以及降低、阻断、抑制、消除或干扰由PD-L2与其一个或更多个结合配偶体(例如PD-1)的相互作用导致的信号转导的其他分子。
“免疫检查点抑制剂”是指抑制免疫检查点蛋白的功能的任何化合物。抑制包括功能降低和完全阻断。特别地,免疫检查点蛋白是人免疫检查点蛋白。因此免疫检查点蛋白抑制剂特别地是人免疫检查点蛋白的抑制剂。
因此,本公开内容提供了通过施用肿瘤抑制剂(例如TUSC2治疗)来提高免疫检查点阻断的效力的方法。如上所述,免疫检查点调高信号(例如,共刺激分子)或调低信号。可通过免疫检查点阻断而被靶向的抑制性免疫检查点分子包括腺苷A2A受体(A2AR)、B7-H3(也被称为CD276)、B和T淋巴细胞弱化子(B and T lymphocyte attenuator,BTLA)、细胞毒性T淋巴细胞相关蛋白4(CTLA-4,也被称为CD152)、吲哚胺2,3-双加氧酶(IDO)、杀伤细胞免疫球蛋白(KIR)、淋巴细胞活化基因-3(LAG3)、程序性死亡蛋白1(PD-1)、T-细胞免疫球蛋白结构域和黏蛋白结构域3(TIM-3)和T细胞活化的V结构域Ig抑制物(VISTA)。特别地,免疫检查点抑制剂靶向PD-1轴和/或CTLA-4。
免疫检查点抑制剂可以是药物,例如小分子、重组形式的配体或受体,或者是抗体,例如人抗体(例如,国际专利公开No.WO2015016718;Pardoll,Nat Rev Cancer,12(4):252-64,2012;二者均通过引用并入本文)。可使用已知的免疫检查点蛋白的抑制剂或其类似物,特别是可使用嵌合的、人源化或人形式的抗体。如技术人员将知晓的,替代和/或等同名称可用于本公开内容中提及的某些抗体。在本发明的上下文中,这样的替代和/或等同名称是可互换的。例如,已知,lambrolizumab也以替代和等同名称MK-3475和派姆单抗为人所知。
预期可使用本领域已知刺激免疫应答的任何免疫检查点抑制剂。这包括直接或间接刺激或增强抗原特异性T淋巴细胞的抑制剂。这些免疫检查点抑制剂包括但不限于靶向涉及PD-L2、LAG3、BTLA、B7H4和TIM3的免疫检查点蛋白和途径的药剂。例如,本领域已知的LAG3抑制剂包括可溶性LAG3(WO2009044273中公开的IMP321或LAG3-Ig,通过引用并入本文)以及阻断人LAG3的小鼠或人源化抗体(例如,WO2008132601中公开的IMP701,通过引用并入本文)或阻断人LAG3的完全人抗体(例如EP 2320940中公开的,通过引用并入本文)。通过使用针对BTLA的阻断剂提供了另一个实例,包括但不限于阻断人BTLA与其配体相互作用的抗体(例如WO2011014438中公开的4C7,通过引用并入本文)。通过使用中和B7H4的药剂提供了另一个实例,包括但不限于针对人B7H4(WO2013025779和WO2013067492中公开的,各自通过引用并入本文)或可溶性重组形式的B7H4(例如US20120177645中公开的,通过引用并入本文)的抗体。通过中和B7-H3的药剂提供了另一个实例,包括但不限于中和人B7-H3的抗体(例如US 20120294796中作为BRCA84D公开的MGA271及衍生物,通过引用并入本文)。通过靶向TIM3的药剂提供了另一个实例,包括但不限于靶向人TIM3的抗体(例如,如WO2013006490A2中公开的,或者由Jones等,J Exp Med.2008;205(12):2763-79公开的抗人TIM3阻断抗体F38-2E2,各自通过引用并入本文)。
A.PD-1轴拮抗剂
T细胞功能障碍或无反应性与抑制性受体程序性死亡1多肽(PD-1)的诱导且持续表达同时发生。因此,本文中提供了PD-1和通过与PD-1相互作用来发信号的其他分子(例如程序性死亡配体1(PD-L1)和程序性死亡配体2(PD-L2))的治疗性靶向。PD-L1在许多癌症中过表达并且常常与不良预后有关(Okazaki T等,Intern.Immun.20O719(7):813)。因此,通过抑制PD-L1/PD-1相互作用与施用肿瘤抑制剂(例如TUSC2治疗)结合改进了治疗癌症的方法。
例如,PD-1轴结合拮抗剂包括PD-1结合拮抗剂、PDL1结合拮抗剂和PDL2结合拮抗剂。“PD-1”的替代名称包括CD279和SLEB2。“PDL1”的替代名称包括B7-H1、B7-4、CD274和B7-H。“PDL2”的替代名称包括B7-DC、Btdc和CD273。在一些实施方案中,PD-1、PDL1和PDL2是人PD-1、PDL1和PDL2。
在一些实施方案中,PD-1结合拮抗剂是抑制PD-1与其配体结合配偶体结合的分子。在一个具体方面,PD-1配体结合配偶体是PDL1和/或PDL2。在另一个实施方案中,PDL1结合拮抗剂是抑制PDL1与其结合配偶体结合的分子。在一个具体方面,PDL1结合配偶体是PD-1和/或B7-1。在另一个实施方案中,PDL2结合拮抗剂是抑制PDL2与其结合配偶体结合的分子。在一个具体方面,PDL2结合配偶体是PD-1。拮抗剂可以是抗体、其抗原结合片段、免疫黏附蛋白、融合蛋白或寡肽。示例性抗体描述于美国专利No.US8735553、US8354509和US8008449中,所有均通过引用并入本文。用于本文中提供的方法的其他PD-1轴拮抗剂在本领域中是已知的,例如美国专利申请No.US20140294898、US2014022021和US20110008369中所述,所有均通过引用并入本文。
在一些实施方案中,PD-1结合拮抗剂是抗PD-1抗体(例如,人抗体、人源化抗体或嵌合抗体)。在一些实施方案中,抗PD-1抗体选自纳武单抗、派姆单抗和CT-011。在一些实施方案中,PD-1结合拮抗剂是免疫黏附蛋白(例如,包含与恒定区(例如,免疫球蛋白序列的Fc区)融合的PDL1或PDL2的胞外或PD-1结合部分的免疫黏附蛋白)。在一些实施方案中,PD-1结合拮抗剂是AMP-224。纳武单抗,也被称为MDX-1106-04、MDX-1106、ONO-4538、BMS-936558和是WO2006/121168中描述的抗PD-1抗体。派姆单抗,也被称为MK-3475、Merck 3475、lambrolizumab、/>和SCH-900475,是WO2009/114335中描述的抗PD-1抗体。CT-011,也被称为hBAT或hBAT-1,是WO2009/101611中描述的抗PD-1抗体。AMP-224,也被称为B7-DCIg,是WO2010/027827和WO2011/066342中描述的PDL2-Fc融合可溶性受体。另外的PD-1结合拮抗剂包括匹地利珠单抗,其也被称为CT-011;MEDI0680,其也被称为AMP-514;和REGN2810。
在一些实施方案中,免疫检查点抑制剂是PD-L1拮抗剂,例如杜伐单抗(Durvalumab),其也被称为MEDI4736;阿特珠单抗(atezolizumab),其也被称为MPDL3280A;或阿维单抗(avelumab),其也被称为MSB00010118C。在某些方面,免疫检查点抑制剂是PD-L2拮抗剂,例如rHIgM12B7。在一些方面,免疫检查点抑制剂是LAG-3拮抗剂,例如但不限于IMP321和BMS-986016。免疫检查点抑制剂可以是腺苷A2a受体(A2aR)拮抗剂,例如PBF-509。
在一些实施方案中,本文中所述的抗体(例如抗PD-1抗体、抗PDL1抗体或抗PDL2抗体)还包含人或鼠恒定区。在另一个方面,人恒定区选自IgG1、IgG2、IgG2、IgG3和IgG4。在另一个具体方面,人恒定区是IgG1。在另一个方面,鼠恒定区选自IgG1、IgG2A、IgG2B和IgG3。在另一个具体方面,抗体具有降低的或最小的效应物功能。在另一个具体方面,最小效应物功能由原核细胞中的产生引起。在另一个具体方面,最小效应物功能由“更少效应物的Fc突变”或无糖基化引起。
因此,本文中使用的抗体可以是无糖基化的。抗体的糖基化通常是N-连接或O-连接的。“N-连接的”是指碳水化合物部分与天冬酰胺残基的侧链的连接。三肽序列天冬酰胺-X-丝氨酸和天冬酰胺-X-苏氨酸(其中X是除了脯氨酸之外的任何氨基酸)是碳水化合物部分与天冬酰胺侧链的酶促连接的识别序列。因此,多肽中这些三肽序列中的任一种的存在产生潜在的糖基化位点。“O-连接的糖基化”是指糖N-乙酰半乳糖胺、半乳糖或木糖中的一个与羟基氨基酸的连接,所述羟基氨基酸最常见的是丝氨酸或苏氨酸,尽管也可使用5-羟基脯氨酸或5-羟基赖氨酸。通过改变氨基酸序列使得上述三肽序列(用于N-连接的糖基化位点)中的一个被去除,来方便地完成从抗体中去除糖基化位点。改变可通过用另外的氨基酸残基(例如,甘氨酸、丙氨酸或保守替换)替换糖基化位点中的天冬酰胺、丝氨酸或苏氨酸残基来进行。
抗体或其抗原结合片段可使用本领域已知的方法例如通过包括以下的过程来制备:在适于产生前述抗PDL1、抗PD-1或抗PDL2抗体或抗原结合片段的条件下培养包含适于表达的形式的核酸的宿主细胞,所述核酸编码任何前述抗PDL1、抗PD-1或抗PDL2抗体或抗原结合片段,以及回收所述抗体或片段。
B.CTLA-4
可以在本文中提供的方法中被靶向的另外的免疫检查点是细胞毒性T淋巴细胞相关蛋白4(CTLA-4),也被称为CD152。人CTLA-4的完整cDNA序列的Genbank登记号为L15006。CTLA-4在T细胞表面上被发现并且当与抗原呈递细胞表面上的CD80或CD86结合时充当“关闭”开关。CTLA4是免疫球蛋白超家族的成员,其在辅助T细胞的表面上表达并向T细胞传递抑制信号。CTLA4与T细胞共刺激蛋白CD28类似,并且这两种分子均与抗原呈递细胞上的CD80和CD86(也分别被称为B7-1和B7-2)结合。CTLA4向T细胞传递抑制信号,而CD28传递刺激信号。胞内CTLA4还在调节性T细胞中被发现并且可能对其功能很重要。通过T细胞受体和CD28的T细胞活化导致CTLA-4(B7分子的抑制性受体)的表达提高。
在一些实施方案中,免疫检查点抑制剂是抗CTLA-4抗体(例如人抗体、人源化抗体或嵌合抗体)、其抗原结合片段、免疫黏附蛋白、融合蛋白或寡肽。
可以使用本领域公知的方法来产生适用于本发明方法的抗人CTLA-4抗体(或来源于其的VH和/或VL结构域)。或者,可以使用本领域公认的抗CTLA-4抗体。例如,公开于以下的抗CTLA-4抗体可用于本文公开的方法中:US 8,119,129、WO 01/14424、WO 98/42752;WO00/37504(CP675,206,也被称为曲美木单抗;原为替西木单抗(ticilimumab))、美国专利No.6,207,156;Hurwitz等,1998。每个上述公开物的教导在此通过引用并入。也可以使用与任何这些本领域公认的抗体竞争与CTLA-4的结合的抗体。例如,人源化CTLA-4抗体描述于国际专利申请No.WO2001014424、WO2000037504和美国专利No.US8017114中;全部通过引用并入本文。
示例性的抗CTLA-4抗体是伊匹单抗(也被称为10D1、MDX-010、MDX-101和)或其抗原结合片段和变体(参见例如WO01/14424)。在另外的实施方案中,抗体包含伊匹单抗的重链和轻链CDR或VR。因此,在一个实施方案中,抗体包含伊匹单抗的VH区的CDR1、CDR2和CDR3结构域,以及伊匹单抗的VL区的CDR1、CDR2和CDR3结构域。在另一个实施方案中,抗体竞争与CTLA-4上的与上述抗体相同的表位的结合,和/或者与CTLA-4上的与上述抗体相同的表位结合。在另一个实施方案中,抗体与上述抗体具有至少约90%的可变区氨基酸序列同一性(例如,与伊匹单抗具有至少约90%、95%或99%的可变区同一性)。
用于调节CTLA-4的其他分子包括可溶性CTLA-4配体和受体(例如美国专利No.US5844905、US5885796和国际专利申请No.WO1995001994和WO1998042752中所述;所有均通过引用并入本文)和免疫黏附蛋白(例如美国专利US8329867中所述,通过引用并入本文)。
C.杀伤免疫球蛋白样受体(KIR)
用于本公开内容的另外的免疫检查点抑制剂是抗KIR抗体。可以使用本领域公知的方法来产生适用于本发明方法的抗人KIR抗体(或来源于其的VH/VL结构域)。
或者,可以使用本领域公认的抗KIR抗体。抗KIR抗体可以与多种抑制性KIR受体交叉反应并增强具有这些受体中的一种或更多种的NK细胞的细胞毒性。例如,抗KIR抗体可与KIR2D2DLl、KIR2DL2和KIR2DL3中的每个结合,并且通过降低、中和和/或逆转由任何或所有这些KIR介导的NK细胞细胞毒性的抑制来增强NK细胞活性。在一些方面,抗KIR抗体不结合KIR2DS4和/或KIR2DS3。例如,可以使用单克隆抗体1-7F9(也被称为IPH2101)、14F1、1-6F1和1-6F5,其描述于WO 2006/003179中,其教导在此通过引用并入。还可以使用与任何这些本领域公认的抗体竞争与KIR结合的抗体。可以使用的其他本领域公认的抗KIR抗体包括,例如,WO 2005/003168、WO 2005/009465、WO 2006/072625、WO 2006/072626、WO 2007/042573、WO 2008/084106、WO 2010/065939、WO 2012/071411和WO 2012/160448中公开的那些,所有均通过引用并入本文。
示例性的抗KIR抗体是利鲁单抗(也被称为BMS-986015或IPH2102)。在另外的实施方案中,抗KIR抗体包含利鲁单抗的重链和轻链互补决定区(complementaritydetermining region,CDR)或可变区(variable region,VR)。因此,在一个实施方案中,抗体包含利鲁单抗的重链可变(VH)区的CDR1、CDR2和CDR3结构域,以及利鲁单抗的轻链可变(VL)区的CDR1、CDR2和CDR3结构域。在另一个实施方案中,抗体与利鲁单抗具有至少约90%的可变区氨基酸序列同一性。
II.肿瘤抑制治疗
在某些方面,涉及用于将核酸或多肽递送至细胞的组合物和方法。特别是,本文提供了纳米颗粒-核酸或纳米颗粒-多肽复合物以及向对象施用这样的复合物的方法。复合物包含与纳米颗粒缔合的TUSC2多肽和/或核酸。本文中使用的“缔合”意指物理缔合、化学缔合或二者。例如,缔合可以涉及共价键、疏水性相互作用、包封、表面吸附等。
多肽和核酸通常难以穿过细胞膜。两种类型的分子均包含带电残基,其阻碍膜结合和膜向细胞的运输。本发明实施方案通过提供促进细胞摄取的纳米颗粒复合物克服了这一困难。
根据本发明实施方案,多肽和/或核酸可以与纳米颗粒缔合以形成纳米颗粒复合物。在一些实施方案中,纳米颗粒是脂质体或其他基于脂质的纳米颗粒,例如基于脂质的囊泡(例如,DOTAP:胆固醇囊泡)。如在癌症治疗中所使用的,脂质体利用癌症新血管系统中增多的窗状孔(fenestration)来提高肿瘤部位处的脂质体浓度。
在另外的实施方案中,纳米颗粒是非脂质纳米颗粒,例如基于氧化铁的超顺磁性纳米颗粒。直径为约10nm至100nm的超顺磁性纳米颗粒足够小以避免被脾隔离(sequester),但足够大以避免被肝清除。该尺寸的颗粒可以渗透非常小的毛细血管并且可以有效地分布在身体组织中。可使用超顺磁性纳米颗粒复合物作为MRI造影剂来鉴定和跟踪那些摄取治疗复合物的细胞。在某些实施方案中,纳米颗粒是半导体纳米晶体或半导体量子点,其二者均可以用于光学成像。在另外的实施方案中,纳米颗粒可以是在二氧化硅核芯之上包含金层的纳米壳。纳米壳的一个优点是可以使用标准化学来使多肽或核酸与金层缀合。在另外的实施方案中,纳米颗粒可以是富勒烯或纳米管(Gupta等,2005)。
根据本发明实施方案,纳米颗粒复合物可以靶向特定组织和细胞。这可以通过使细胞靶向部分与纳米颗粒缀合来实现。靶向部分可以是,但不限于,蛋白质、肽、脂质、类固醇、糖、碳水化合物或合成化合物。细胞靶向部分(例如配体)识别其在细胞表面上的同源受体并与之结合。类似地,抗体可以通过识别其在细胞表面上的同源抗原而发挥细胞靶向部分的作用。在某些实施方案中,本文提供的靶向纳米颗粒复合物可以增强疾病治疗的特异性并提高进入靶细胞的治疗剂的量。
A.纳米颗粒
本文中使用的术语“纳米颗粒”是指尺寸为1nm至1,000nm的任何材料。在一些实施方案中,纳米颗粒的尺寸为50nm至500nm。在本发明实施方案中使用的纳米颗粒包括这样的纳米级材料,例如基于脂质的纳米颗粒、超顺磁性纳米颗粒、纳米壳、半导体纳米晶体、量子点、基于聚合物的纳米颗粒、基于硅的纳米颗粒、基于二氧化硅的纳米颗粒、基于金属的纳米颗粒、富勒烯和纳米管(Ferrari,2005)。多肽或核酸与纳米颗粒的缀合为结构提供了靶向递送、受控释放、增强细胞摄取和胞内运输以及体外和体内治疗肽的分子成像的潜在应用(West,2004;Stayton等,2000;Ballou等,2004;Frangioni,2003;Dubertret等,2002;Michalet等,2005;Dwarakanath等,2004)。
1.基于脂质的纳米颗粒
基于脂质的纳米颗粒包含脂质体、脂质制剂和基于脂质的囊泡(例如,DOTAP:胆固醇囊泡)。基于脂质的纳米颗粒可以是带正电荷、带负电荷或中性的。在某些实施方案中,基于脂质的纳米颗粒是带中性电荷的(例如,DOPC脂质体)。
“脂质体”是通用术语,包括通过产生封闭的脂双层或脂质聚集体形成的多种单层和多层脂质载体。脂质体可表征为具有囊泡结构,所述囊泡结构具有通常包含磷脂的双层膜,和通常包含水性组合物的内部介质。本文提供的脂质体包括单层脂质体,多层脂质体和多囊脂质体。本文提供的脂质体可带正电荷、带负电荷或带中性电荷。在某些实施方案中,脂质体是电荷中性的。
多层脂质体具有由水性介质分隔的多个脂质层。它们在包含磷脂的脂质悬浮在过量的水溶液中时自发形成。脂质组分在形成封闭结构之前经历自身重排并包载脂双层之间的水和溶解的溶质(Ghosh和Bachhawat,1991)。亲脂性分子或具有亲脂性区域的分子也可溶解在脂双层中或与脂双层缔合。
在一些具体方面,多肽或核酸可例如包封在脂质体的水性内部、散布在脂质体的脂双层内、通过与脂质体和多肽/核酸二者缔合的连接分子与脂质体连接、包埋在脂质体中、与脂质体复合等。
如本领域普通技术人员已知的,根据本发明实施方案使用的脂质体可以通过不同方法制备。例如,将磷脂(Avanti Polar Lipids,Alabaster,AL),例如如中性磷脂二油酰基磷脂酰胆碱(dioleoylphosphatidylcholine,DOPC)溶解在叔丁醇中。然后将脂质与多肽、核酸和/或其他组分混合。将吐温20添加到脂质混合物中,使得吐温20为组合物重量的约5%。向该混合物中添加过量的叔丁醇,使得叔丁醇的体积为至少95%。涡旋混合物,在干冰/丙酮浴中冷冻并冻干过夜。冻干制剂被储存在-20℃,并可以使用长达三个月。当需要时,将冻干脂质体在0.9%盐水中重构。
或者,脂质体可以通过将脂质在容器(例如玻璃、梨形烧瓶)中的溶剂中混合来制备。容器的体积应比预期的脂质体混悬液的体积大十倍。使用旋转蒸发器,在负压下在约40℃下去除溶剂。溶剂通常在约5分钟至2小时内去除,取决于所期望的脂质体体积。组合物可以在真空干燥器中进一步干燥。干燥的脂质通常由于随着时间的推移趋于恶化而在约1周后丢弃。
干燥的脂质可以在无菌且无热原的水中在约25mM至50mM磷脂下通过摇动直至所有脂质膜重新悬浮而水合。然后可将水性脂质体分成等分试样,将每个放置于小瓶中,冻干并在真空下密封。
如上所述制备的干燥脂质或冻干脂质体可脱水并在蛋白质或肽的溶液中重构,并用合适的溶剂(例如DPBS)稀释至合适的浓度。然后将混合物在涡旋混合器中剧烈摇动。通过在29,000g下离心去除未包封的其他材料(例如包括但不限于激素、药物、核酸构建体等的试剂),并洗涤脂质体颗粒。将经洗涤的脂质体以合适的总磷脂浓度重新悬浮,例如约50mM至200mM。包封的其他材料或活性剂的量可以根据标准方法确定。在确定包封在脂质体制剂中的其他材料或活性剂的量之后,可将脂质体稀释至合适的浓度并储存在4℃直至使用。包含脂质体的药物组合物通常包含无菌可药用载体或稀释剂,例如水或盐水溶液。
在另外的替代方法中,脂质体可以根据其他已知的实验室程序制备(例如,参见Bangham等,1965;Gregoriadis,1979;Deamer和Uster,1983;Szoka和Papahadjopoulos,1978,各自在相关部分通过引用并入本文)。对于本发明实施方案有用的其他脂质体包括阳离子脂质体,例如,如WO02/100435A1、美国专利5,962,016、美国申请2004/0208921、WO03/015757A1、WO04029213A2、美国专利5,030,453和美国专利6,680,068中所述,其所有均在没有放弃权利要求的情况下通过引用整体并入本文。制造脂质体的方法也描述于WO04/002453A1中。中性脂质可以并入阳离子脂质体中(例如,Farhood等,1995)。可用于某些实施方案的多种中性脂质体在美国专利5,855,911中公开,其通过引用并入本文。这些方法的各自包载水性物质的能力和它们各自的水性空间-脂质比不同。
脂质体的尺寸根据合成方法而变化。本发明实施方案中的脂质体可以是多种尺寸。在某些实施方案中,脂质体是小的,例如,外径小于约100nm、约90nm、约80nm、约70nm、约60nm或小于约50nm。例如,一般来说,在核酸并入之前,根据本发明实施方案使用的DOTAP:胆固醇脂质体包含约50nm至500nm的尺寸。这样的脂质体制剂还可以通过颗粒电荷(ζ电位)和/或光密度(OD)来限定。例如,DOTAP:胆固醇脂质体制剂在核酸并入之前通常包含小于0.45的OD400。同样地,溶液中这样的颗粒的总电荷可以通过约50mV至80mV的ζ电位来限定。
在制备这样的脂质体中,可以使用本文所述的,或者如本领域普通技术人员已知的任何方案。制备脂质体的另外的非限制性实例描述于美国专利4,728,578、4,728,575、4,737,323、4,533,254、4,162,282、4,310,505和4,921,706;国际申请PCT/US85/01161和PCT/US89/05040;英国专利申请GB 2193095A;Mayer等,1986;Hope等,1985;Mayhew等,1987;Mayhew等,1984;Cheng等,1987;和Liposome Technology,1984,各自通过引用并入本文)。
在某些实施方案中,基于脂质的纳米颗粒是中性脂质体(例如,DOPC脂质体)。本文中使用的“中性脂质体”或“不带电荷的脂质体”被限定为具有一种或更多种脂质组分的脂质体,所述脂质组分产生基本上中性的净电荷(基本上不带电荷)。“基本上中性”或“基本上不带电荷”意指给定群体(例如,脂质体群体)中的少数(如果有的话)脂质组分包含未被另一组分的相反电荷消除的电荷(即,少于10%的组分包含未消除的电荷,更优选少于5%,最优选少于1%)。在某些实施方案中,中性脂质体可以主要包含在生理条件下(即,在约pH 7下)本身是中性的脂质和/或磷脂。
本发明实施方案的脂质体和/或基于脂质的纳米颗粒可包含磷脂。在某些实施方案中,单种磷脂可用于产生脂质体(例如,中性磷脂(例如DOPC),可用于产生中性脂质体)。在另外的实施方案中,可使用多于一种的磷脂来产生脂质体。
磷脂包括,例如,磷脂酰胆碱、磷脂酰甘油和磷脂酰乙醇胺;因为磷脂酰乙醇胺和磷脂酰胆碱在生理条件下(即,在约pH 7下)是不带电荷的,所以这些化合物可特别用于产生中性脂质体。在某些实施方案中,磷脂DOPC用于产生不带电荷的脂质体。在某些实施方案中,可使用非磷脂(例如胆固醇)的脂质。
磷脂包括甘油磷脂和某些鞘脂。磷脂包括但不限于二油酰基磷脂酰胆碱(“DOPC”)、卵磷脂酰胆碱(“EPC”)、二月桂酰基磷脂酰胆碱(“DLPC”)、二肉豆蔻酰基磷脂酰胆碱(“DMPC”)、二棕榈酰基磷脂酰胆碱(“DPPC”)、二硬脂酰基磷脂酰胆碱(“DSPC”)、1-肉豆蔻酰基-2-棕榈酰基磷脂酰胆碱(“MPPC”)、1-棕榈酰基-2-肉豆蔻酰基磷脂酰胆碱(“PMPC”)、1-棕榈酰基-2-硬脂酰基磷脂酰胆碱(“PSPC”)、1-硬脂酰基-2-棕榈酰基磷脂酰胆碱(“SPPC”)、二月桂酰基磷脂酰甘油(“DLPG”)、二肉豆蔻酰基磷脂酰甘油(“DMPG”)、二棕榈酰基磷脂酰甘油(“DPPG”)、二硬脂酰基磷脂酰甘油(“DSPG”)、二硬脂酰基鞘磷脂(“DSSP”)、二硬脂酰基磷脂酰乙醇胺(“DSPE”)、二油酰基磷脂酰甘油(“DOPG”)、二肉豆蔻酰基磷脂酸(“DMPA”)、二棕榈酰基磷脂酸(“DPPA”)、二肉豆蔻酰基磷脂酰乙醇胺(“DMPE”)、二棕榈酰基磷脂酰乙醇胺(“DPPE”)、二肉豆蔻酰基磷脂酰丝氨酸(“DMPS”)、二棕榈酰基磷脂酰丝氨酸(“DPPS”)、脑磷脂酰丝氨酸(“BPS”)、脑鞘磷脂(“BSP”)、二棕榈酰基鞘磷脂(“DPSP”)、二肉豆蔻酰基磷脂酰胆碱(“DMPC”)、1,2-二硬脂酰-sn-甘油基-3-磷酸胆碱(“DAPC”)、1,2-二花生酰-sn-甘油基-3-磷酸胆碱(“DBPC”)、1,2-二十二碳烯酰-sn-甘油-3-磷酸胆碱(“DEPC”)、二油酰基磷脂酰乙醇胺(“DOPE”)、棕榈酰氧基磷脂酰胆碱(“POPC”)、棕榈酰氧基磷脂酰乙醇胺(“POPE”)、溶血磷脂酰胆碱、溶血磷脂酰乙醇胺和二亚油酰基磷脂酰胆碱。
磷脂可以来自天然或合成来源。然而,在某些实施方案中,不使用来自天然来源的磷脂(例如卵磷脂酰胆碱或大豆磷脂酰胆碱、脑磷脂酸、脑或植物磷脂酰肌醇,心脏心磷脂和植物磷脂酰乙醇胺或细菌磷脂酰乙醇胺)作为主要磷脂(即,构成总磷脂组成的50%或更多),因为这可能导致所得脂质体的不稳定性和渗漏。
2.DOTAP:胆固醇纳米颗粒
在某些实施方案中,基于脂质的囊泡是DOTAP:胆固醇纳米颗粒。DOTAP:胆固醇纳米颗粒是通过将阳离子脂质DOTAP(1,2-双(油酰氧基)-3-(三甲基氨基)-丙烷)与胆固醇混合来制备的。用DNA制备的囊泡可以形成结构(被称为“夹心(sandwich)”),其中DNA似乎在两个脂双层之间浓缩(美国专利6,770,291和6,413,544)。
DOTAP:胆固醇-核酸复合物可以如以下非限制性实施例中那样制备。如前所述(美国专利6,770,291和6,413,544;Templeton,1997)合成DOTAP:胆固醇(DC)纳米颗粒(尺寸为50nm至500nm)。简言之,测量420mgDOTAP和208mg胆固醇并与30ml氯仿混合在一起。然后使混合物在旋转蒸发器上干燥30分钟并冷冻干燥15分钟。将干燥的混合物在30mlD5W中通过在50℃下涡旋45分钟和在37℃下涡旋10分钟进行重构。将混合物进行低频超声5分钟以形成脂质体。然后将DOTAP:胆固醇脂质体加热至50℃并依次通过1.0、0.45、0.2和0.1μm无菌Whatman过滤器过滤。将合成的纳米颗粒储存在4℃下并用于制备纳米颗粒复合物。配制的DOTAP:胆固醇脂质体应均匀分散,其中颗粒尺寸为50nm至250nm,OD400小于0.45,ζ电位为50mV至80mV。剩余的CHCl3水平应低于60ppm。
为了制备DOTAP:胆固醇-核酸纳米颗粒,将240μl脂质体(参见上文)在室温下在360μl D5W中稀释。向混合物添加DNA(约5mg/ml)至总体积为600μl。将混合物在移液管中上下移动以混合。一旦沉降,混合物的OD400应为0.65至0.95,颗粒尺寸应为200nm至500nm,并被确认为革兰氏染色阴性。将脂质体复合物储存在3℃至28℃并尽可能少地搅拌。
B.靶向纳米颗粒
通过添加配体来实现靶向递送而不影响纳米颗粒递送其有效载荷的能力。可以预期,这将使得能够递送至特定的细胞、组织和器官。基于配体的递送系统的靶向特异性基于配体受体在不同的细胞类型上的分布。靶向配体可非共价地或共价地与纳米颗粒缔合,并且可以通过如本文所讨论的多种方法与纳米颗粒缀合。
可用于靶向纳米颗粒的蛋白质或肽的实例包括转铁蛋白、乳铁蛋白、TGF-α、神经生长因子、白蛋白、HIV Tat肽、RGD肽和胰岛素以及其他(Gupta等,2005;Ferrari,2005)。
C.TUSC2表达载体
术语“载体(vector)”用于指载体核酸分子,其中可以插入核酸序列以引入到其可以在此进行复制的细胞中。核酸序列可以是“外源的”,这意味着其对于引入载体的细胞是外来的,或者该序列与细胞中的序列同源但在宿主细胞核酸内该序列通常不存在的位置中。载体包括质粒、黏粒、病毒(噬菌体、动物病毒和植物病毒)和人工染色体(例如,YAC)。本领域技术人员将能够通过标准重组技术构建载体(参见例如Maniatis等,1989和Ausubel等,1994,二者均通过引用并入本文)。
术语“表达载体”是指包含编码能够被转录的RNA的核酸的任何类型的遗传构建体。在一些情况下,随后将RNA分子翻译为蛋白质、多肽或肽。在另外的情况下,这些序列例如在反义分子或核酶的产生中不翻译。表达载体可包含多种“控制序列”,其是指在特定的宿主细胞中可操作地连接的编码序列之转录和可能的翻译所必需的核酸序列。除了控制转录和翻译的控制序列之外,载体和表达载体还可包含用于其他功能的核酸序列,并且在下文中描述。
在某些实施方案中,本文提供了核酸TUSC2编码序列的用途。例如,这样的载体可以用于在对象体内重组产生TUSC2多肽和/或用于在对象体内表达TUSC2。考虑到数种不同的密码子编码单一氨基酸的能力,在序列仍然编码相同的蛋白质或多肽的同时,可对序列进行修饰。密码子选择的优化也可以根据用于重组表达的特定生物体进行,或者可以针对人细胞(例如癌细胞)中的最大表达进行优化。根据本发明实施方案使用的载体另外包含控制基因表达和/或有助于载体生产和纯化的元件。
1.启动子和增强子
“启动子”是控制序列,其是控制转录的起始和速率的核酸序列的区域。其可包含调节蛋白和分子(例如RNA聚合酶和其他转录因子)可与之结合的遗传元件,以启动核酸序列的特异性转录。短语“可操作地定位”,“可操作地连接”、“在控制下”和“在转录控制下”意指启动子处于相对于核酸序列的正确的功能位置和/或取向以控制该序列的转录起始和/或表达。
启动子通常包含用于定位RNA合成的起始位点的序列。其最为人知的实例是TATA盒,但在一些缺少TATA盒的启动子(例如哺乳动物末端脱氧核苷酸转移酶基因的启动子和SV40晚期基因的启动子)中,覆盖起始位点的离散元件本身有助于确定起始位置。另外的启动子元件调节转录起始的频率。通常,这些位于起始位点上游30至110bp的区域,尽管已经显示许多启动子也包含在起始位点下游的功能元件。为了使编码序列“在启动子的控制下”,将转录阅读框的转录起始位点的5’端定位于所选择的启动子的“下游”(即3’)。“上游”启动子刺激DNA的转录并促进编码的RNA的表达。
启动子元件之间的间隔通常是灵活的,使得当元件相对于彼此倒转或移动时保持启动子功能。在tk启动子中,在活性开始下降之前启动子元件之间的间隔可以提高到50bp。取决于启动子,似乎各个元件可以协作地或独立地发挥功能来激活转录。启动子可与或可不与“增强子”结合使用,“增强子”是指参与核酸序列的转录激活的顺式作用调控序列。
启动子可与核酸序列天然相关,如可通过分离位于编码区段和/或外显子上游的5’非编码序列获得的。这样的启动子可以被称为“内源”或“同源”。类似地,增强子可与核酸序列自然缔合、位于该序列的上游或下游。或者,通过将编码核酸区段置于重组或异源启动子的控制下将获得某些优点,所述启动子是指在其天然环境中通常不与核酸序列相缔合的启动子。重组或异源增强子也是指在其天然环境中通常不与核酸序列相缔合的增强子。这样的启动子或增强子可包括病毒启动子和增强子,例如CMV启动子。
当然,重要的是使用有效指导DNA区段在选择用于表达的细胞器、细胞、组织、器官或生物体中表达的启动子和/或增强子。分子生物学领域的技术人员通常知晓启动子、增强子和细胞类型组合用于蛋白质表达的用途(参见例如Sambrook等,1989,通过引用并入本文)。所使用的启动子可以是组成型、组织特异性、诱导型和/或在合适的条件下可用于指导引入的DNA区段的高水平表达,例如有利于大规模生产重组蛋白和/或肽。启动子可为异源的或内源的。
此外,还可以使用任何启动子/增强子组合(根据例如真核启动子数据库EPDB,WWW.epd.isb-sib.ch/)来驱动表达。使用T3、T7或SP6胞质表达系统是另一个可能的实施方案。如果提供合适的细菌聚合酶作为递送复合物的一部分或作为另外的遗传表达构建体,真核细胞可以支持来自某些细菌启动子的胞质转录。
2.翻译起始信号
编码序列的有效翻译也可需要特定的起始信号。这些信号包括ATG起始密码子或邻近序列。可能需要提供包含ATG起始密码子的外源翻译控制信号。本领域普通技术人员将能够容易地对此进行确定并提供必需的信号。公知的是起始密码子必须与期望编码序列的阅读框“同框(in-frame)”,以确保整个插入片段的翻译。外源翻译控制信号和起始密码子可以是天然的或合成的。通过包含合适的转录增强子元件可增强表达效率。
3.多克隆位点
载体可包含多克隆位点(MCS),多克隆位点是包含多个限制酶位点的核酸区域,所述限制酶位点中的任何一个可以与标准重组技术结合用于消化载体(参见例如Carbonelli等,1999,Levenson等,1998,和Cocea,1997,通过引用并入本文)。“限制酶消化”是指用仅在核酸分子中的特定位置发挥功能的酶对核酸分子进行催化切割。这些限制酶中的许多是市售的。这样的酶的使用是本领域技术人员广泛理解的。通常,使用在MCS内切割的限制性酶将载体线性化或片段化,以使外源序列能够连接至载体。“连接”是指在两个核酸片段之间形成磷酸二酯键的过程,所述两个核酸片段可彼此连续或可不连续。涉及限制酶和连接反应的技术是重组技术领域的技术人员公知的。
4.剪接位点
大多数转录的真核生物RNA分子将经历RNA剪接以从初级转录物去除内含子。包含基因组真核序列的载体可能需要供体和/或受体剪接位点以确保对转录物的正确加工用于蛋白质表达(参见例如Chandler等,1997,通过引用并入本文)。包含这样的剪接位点还可以通过避免所得RNA转录物的无义介导的衰变来增强表达。
5.终止信号
本发明实施方案的载体或构建体将通常包含至少一种终止信号。“终止信号”或“终止子”由通过RNA聚合酶参与RNA转录物的特异性终止的DNA序列构成。因此,在某些实施方案中,预期了结束RNA转录物产生的终止信号。终止子可能是在体内达到理想信使水平所必需的。
预期用于本发明实施方案的终止子包括本文所述或本领域普通技术人员已知的任何已知的转录终止子,包括但不限于例如基因的终止序列,例如牛生长激素终止子或病毒终止序列,例如如SV40终止子。在某些实施方案中,终止信号可能缺少可转录或可翻译的序列,例如由于序列截短。6.多腺苷酸化信号
在表达,特别是在真核生物表达中,通常将包含多腺苷酸化信号以实现转录物的合适的多腺苷酸化。多腺苷酸化信号的性质并不被认为是成功实践本发明实施方案的关键,并且可采用任意这样的序列。一些优选的实施方案包括SV40多腺苷酸化信号或牛生长激素多腺苷酸化信号,其是方便的且已知在多种靶细胞中良好地起作用。多腺苷酸化可提高转录物的稳定性或可促进胞质运输。
7.复制起点
为了在宿主细胞中使载体增殖,其可包含一个或更多个复制起始位点(通常被称为“ori”),所述位点是复制在此处起始的特异性核酸序列。或者,如果宿主细胞是酵母,则可以使用自主复制序列(ARS)。
8.选择性和筛选性标志物
在某些实施方案中,可通过在表达载体中包含标志物来体外或体内鉴定包含本文提供的核酸构建体的细胞。这样的标志物会赋予细胞以可鉴定变化,从而允许容易地鉴定包含表达载体的细胞。通常,选择性标志物是赋予允许选择之特性的标志物。阳性选择性标志物是其中标志物的存在允许其选择的标志物,而阴性选择性标志物是其中标志物的存在阻止其选择的标志物。阳性选择性标志物的实例是抗药性标志物。
通常包含药物选择标志物有助于转化体的克隆和鉴定,例如赋予针对新霉素、嘌呤霉素、潮霉素、DHFR、GPT、博来霉素(zeocin)和组氨醇之抗性的基因是有用的选择性标志物。除了赋予允许基于条件实施来区分转化体之表型的标志物之外,还预期了其他类型的标志物,包括筛选性标志物,例如GFP,其基础是比色分析。或者,可利用筛选性酶,例如单纯疱疹病毒胸苷激酶(tk)或氯霉素乙酰转移酶(CAT)。本领域技术人员还知晓如何使用免疫标志物,可能与FACS分析结合。认为所使用的标志物不重要,只要其能够与编码基因产物的核酸同时表达即可。选择性标志物和筛选性标志物的另外的实例是本领域技术人员公知的。
9.质粒载体
在某些实施方案中,预期质粒载体用于转化宿主细胞。一般来说,包含来源于与宿主细胞相容的物种之复制子和控制序列的质粒载体与这些宿主一起使用。载体通常携带复制位点,以及能够在转化细胞中提供表型选择的标记序列。在一个非限制性实例中,通常使用来源于大肠杆菌物种的质粒pBR322的衍生物转化大肠杆菌。pBR322包含氨苄青霉素和抗四环素抗性基因,因此提供了鉴定转化细胞的简便方法。pBR质粒或其他微生物质粒或噬菌体还必须包含或经修饰以包含例如可被微生物生物体用于表达其自身蛋白质的启动子。
此外,包含与宿主微生物相容的复制子和控制序列的噬菌体载体可以用作与这些宿主相关的转化载体。例如,噬菌体λGEMTM-11可用于制备可以用于转化宿主细胞的重组噬菌体载体,例如大肠杆菌LE392。
另外的有用的质粒载体包括pIN载体(Inouye等,1985);和pGEX载体,用于产生谷胱甘肽S转移酶(GST)可溶性融合蛋白,用于后期的纯化和分离或切割。其他合适的融合蛋白是具有β-半乳糖苷酶、泛素等的融合蛋白。
包含表达载体的细菌宿主细胞(例如大肠杆菌)在许多合适的培养基中的任一种中生长(例如LB)。如本领域技术人员所理解的,通过使宿主细胞与对某些启动子具有特异性的试剂接触,例如通过向培养基添加IPTG或通过将孵育温度转换到更高的温度,可诱导重组蛋白在某些载体中的表达。在将细菌培养另外一段时间之后(一般为2至24小时),通过离心收集细胞并洗涤以去除剩余的培养基。
10.病毒载体
某些病毒通过受体介导的胞吞感染细胞或进入细胞,和整合到宿主细胞基因组中并稳定且有效地表达病毒基因的能力使其成为将外来核酸转移到细胞(例如,哺乳动物细胞)中的有吸引力的候选者。因此可利用编码和表达TUSC2的病毒。以下描述了可用于递送TUSC2核酸的病毒载体的非限制性实例。
腺病毒载体。一种用于递送核酸的特殊方法涉及使用腺病毒表达载体。虽然已知腺病毒载体整合到基因组DNA中的能力低,但是该特征被这些载体提供的高效率基因转移所抵消。“腺病毒表达载体”意指包括包含足以(a)支持构建体包装和(b)最终表达在其中克隆的组织特异性或细胞特异性构建体之腺病毒序列的那些构建体。遗传组织或腺病毒(36kb的线性双链DNA病毒)的知识允许将大片腺病毒DNA替换为多至7kb的外来序列(Grunhaus和Horwitz,1992)。
AAV载体。可使用腺病毒辅助转染将核酸引入细胞中。已经在使用腺病毒偶联系统的细胞系统中报道了提高的转染效率(Kelleher和Vos,1994;Cotten等,1992;Curiel,1994)。腺相关病毒(Adeno-associated virus,AAV)具有高整合频率并且它可以感染非分裂细胞,因此使其可用于将基因递送至哺乳动物细胞中(例如,递送至组织培养物中(Muzyczka,1992)或体内)。AAV具有广泛的宿主感染范围(Tratschin等,1984;Laughlin等,1986;Lebkowski等,1988;McLaughlin等,1988)。关于rAAV载体的产生和用途的细节描述于美国专利5,139,941和4,797,368,各自通过引用并入本文。
逆转录病毒载体。逆转录病毒有能力将它们的基因整合到宿主基因组中,转移大量的外来遗传物质,感染广谱的物种和细胞类型,并被包装在特殊的细胞系中(Miller,1992)。为了构建逆转录病毒载体,将核酸(例如,编码目的蛋白质的核酸)代替某些病毒序列而插入到病毒基因组中以产生复制缺陷型病毒。为了产生病毒粒子,构建了包含gag、pol和env基因但无LTR以及包装组分的包装细胞系(Mann等,1983)。当将包含cDNA与逆转录病毒LTR和包装序列的重组质粒引入特殊细胞系(例如如通过磷酸钙沉淀)中时,包装序列允许重组质粒的RNA转录物被包装成病毒颗粒,然后所述病毒颗粒分泌到培养基中(Nicolas和Rubinstein,1988;Temin,1986;Mann等,1983)。然后收集包含重组逆转录病毒的培养基,任选地浓缩并用于基因转移。逆转录病毒载体能够感染多种细胞类型。然而,整合和稳定表达需要宿主细胞的分裂(Paskind等,1975)。
慢病毒是复杂的逆转录病毒,其除了常见的逆转录病毒基因gag、pol和env之外还包含具有调节或结构功能的其他基因。慢病毒载体是本领域公知的(参见,例如,Naldini等,1996;Zufferey等,1997;Blomer等,1997;美国专利6,013,516和5,994,136)。慢病毒的一些实例包括人免疫缺陷病毒:HIV-1、HIV-2和猿猴免疫缺陷病毒:SIV。通过对HIV毒力基因进行多次减毒(例如,缺失基因env、vif、vpr、vpu和nef)产生慢病毒载体,使得载体在生物学上是安全的。
其他病毒载体。其他病毒载体可用作本发明实施方案中的疫苗构建体。可使用来源于以下病毒的载体,例如痘苗病毒(Ridgeway,1988;Baichwal和Sugden,1986;Coupar等,1988)、辛德毕斯病毒(sindbis virus)、巨细胞病毒和单纯疱疹病毒。它们为数种哺乳动物细胞提供了数个有吸引力的特征(Friedmann,1989;Ridgeway,1988;Baichwal和Sugden,1986;Coupar等,1988;Horwich等,1990)。
经修饰的病毒。待传递的核酸可容纳在已经被工程化以表达特异性结合配体的感染性病毒中。因此病毒颗粒将与靶细胞的同源受体特异性地结合并将内容物递送至细胞。基于逆转录病毒的化学修饰通过将乳糖残基化学添加到病毒包膜中而开发了旨在允许逆转录病毒载体的特异性靶向的新方法。这种修饰可以允许通过唾液酸糖蛋白受体的肝细胞的特异性感染。
设计了靶向重组逆转录病毒的另外的方法,其中使用了针对逆转录病毒包膜蛋白和针对特定细胞受体的生物素化抗体。抗体通过使用链霉抗生物素蛋白经由生物素组分偶联(Roux等,1989)。使用针对主要组织相容性复合体I类和II类抗原的抗体,其证明了在体外用同向性病毒感染多种带有这些表面抗原的人细胞(Roux等,1989)。
III.药物制剂
本文提供的药物组合物包含有效量的一种或更多种TUSC2治疗剂和/或免疫检查点抑制剂,以及任选地,溶解或分散在可药用载体中的另外的药剂。短语“可药用或药理学上可接受的”是指当适当地向动物(例如如人)施用时不产生不利的、变应性或其他不良反应的分子实体和组合物。制备至少包含TUSC2核酸、肽或纳米颗粒复合物或者另外的活性成分的药物组合物将根据本公开内容为技术人员所知,如Remington′s PharmaceuticalSciences,第18版.Mack Printing Company,1990所举例说明的,通过引用并入本文。此外,对于动物(例如,人)施用,应当理解,制剂应符合FDA生物标准办公室(FDA Office ofBiological Standards)所要求的无菌性、热原性、一般安全性和纯度标准。
本文中所使用的“可药用载体”包括任何和所有溶剂、分散介质、涂层、表面活性剂、抗氧化剂、防腐剂(例如,抗细菌剂、抗真菌剂)、等张剂、吸收延迟剂、盐类、防腐剂、药物、药物稳定剂、凝胶剂、黏合剂、赋形剂、崩解剂、润滑剂、甜味剂、芳香剂、染料、类似物质及其组合,如本领域普通技术人员所知(参见,例如,Remington's PharmaceuticalSciences,第18版.Mack Printing Company,1990,第1289-1329页,通过引用并入本文)。除非任何常规载体与活性成分不相容,否则预期其在治疗性组合物或药物组合物中的使用。
在某些实施方案中,药物组合物可包含不同类型的载体,这取决于其是以固体、液体或气雾剂形式施用,以及对于例如注射的施用途径是否需要是无菌的。在某些实施方案中,本文提供的药物组合物可通过静脉内、皮内、动脉内、腹膜内、病灶内、颅内、关节内、前列腺内、胸膜内、气管内、鼻内、玻璃体内、阴道内、直肠内、表面、瘤内、肌内、腹膜内、皮下、结膜下、囊内、经黏膜、心包内、脐内、眼内、经口、经表面、局部、吸入(例如,气雾剂吸入)、注射、输注、连续输注、直接局部灌注浸浴靶细胞、通过导管、通过灌洗、以乳膏剂、以脂质组合物(例如,脂质体),或通过本领域普通技术人员已知其他方法或前述的任意组合进行施用(参见,例如,Remington’s Pharmaceutical Sciences,第18版.Mack Printing Company,1990,通过引用并入本文)。
在某些实施方案中,腹膜内施用药物组合物。在另外的实施方案中,腹膜内施用药物组合物以治疗癌症(例如,癌性肿瘤)。例如,可腹膜内施用药物组合物以治疗胃肠道癌。在某些实施方案中,可能期望将药物组合物施用到肿瘤中或肿瘤附近。
在某些优选的实施方案中,经口施用药物组合物以治疗癌症(例如,胃肠道癌)。
在某些实施方案中,向患者施用的组合物的实际剂量可以由物理和生理因素来确定,所述因素例如体重、病症的严重程度、所治疗疾病的类型、先前或同时治疗干预、患者的特发病和施用途径。在任何事件下,负责施用的医疗人员将确定组合物中活性成分的浓度和用于个体对象的合适剂量。
在某些实施方案中,药物组合物可包含例如至少约0.1%的活性化合物。在另外的实施方案中,活性化合物可包含单位重量的约2%至约75%,或例如约25%至约60%,以及从中可推论出的任何范围。在另外的非限制性实施例中,剂量还可包含每次施用约1微克/kg/体重、约5微克/kg/体重、约10微克/kg/体重、约15微克/kg/体重、约20微克/kg/体重、约25微克/kg/体重、约30微克/kg/体重、约35微克/kg/体重、约0.04毫克/kg/体重、约0.05毫克/kg/体重、约0.06毫克/kg/体重、约0.07毫克/kg/体重、约0.08毫克/kg/体重、约0.09毫克/kg/体重、约0.1毫克/kg/体重、约0.2毫克/kg/体重、至约0.5mg/kg/体重或更多,以及从中可推论出的任何范围。可从本文中所列数字推论出之范围的非限制性实例中,基于上述数量,可以施用约0.01mg/kg/体重至约0.1mg/kg/体重、约0.04微克/kg/体重至约0.08毫克/kg/体重。
在任何情况下,组合物可包含多种抗氧化剂以延迟一种或更多种组分的氧化。另外,防止微生物作用可通过防腐剂(例如多种抗细菌剂和抗真菌剂)来实现,包括但不限于对羟基苯甲酸酯类(例如对羟基苯甲酸甲酯、对羟基苯甲酸丙酯)、氯丁醇、苯酚、山梨酸、硫柳汞或其组合。
可将一种或更多种肽、纳米颗粒复合物或另外的药剂配制成游离碱、中性或盐形式的组合物。可药用盐包括酸加成盐,例如与蛋白质组合物的游离氨基形成的盐,或与无机酸(例如如盐酸或磷酸)形成的盐,或与有机酸(例如乙酸、草酸、酒石酸或扁桃酸)形成的盐。与游离羧基形成的盐也可来源于无机碱,例如钠、钾、铵、钙或铁的氢氧化物;或有机碱例如异丙胺、三甲胺、组胺或普鲁卡因。
在其中组合物为液体形式的一些实施方案中,载体可以是溶剂或分散介质,包括但不限于水、乙醇、多元醇(例如,甘油、丙二醇、液体聚乙二醇等)、脂质(例如,甘油三酯、植物油、脂质体)及其组合。合适的流动性可以例如通过以下方法来保持:使用例如卵磷脂的涂层;通过在载体(例如液体多元醇或脂质)中分散来维持所需的颗粒尺寸;使用表面活性剂,例如如羟丙基纤维素;或此类方法的组合。在许多情况下,优选包含等张剂,例如如糖、氯化钠或其组合。
在另外的实施方案中,可以在本发明实施方案中使用滴眼剂、鼻用溶液或喷雾剂、气雾剂或吸入剂。通常将这样的组合物设计成与靶组织类型相容。在一个非限制性实例中,鼻用溶液通常是设计为以滴剂或喷雾剂施用于鼻部通道的水性溶液。制备鼻用溶液使得它们在许多方面类似于鼻分泌物,从而维持正常的纤毛作用。因此,在一些优选的实施方案中,水性鼻用溶液通常是等张的或略微缓冲的,以维持约5.5至约6.5的pH。此外,如果需要,可在制剂中包含抗微生物防腐剂(其类似于眼用制剂中使用的那些)、药物或合适的药物稳定剂。例如,多种市售鼻用制剂是已知的并且包含例如抗生素或抗组胺药的药物。
在某些实施方案中,制备一种或更多种多肽、核酸或纳米颗粒复合物用于通过经口摄入等途径施用。在这些实施方案中,固体组合物可包含例如溶液剂、混悬剂、乳剂、片剂、丸剂、胶囊剂(例如硬壳或软壳明胶胶囊剂)、持续释放制剂、含服组合物、锭剂、酏剂、混悬剂、糖浆剂、晶片剂,或其组合。经口组合物可直接并入饮食的食物中。用于经口施用的优选载体包括惰性稀释剂、可同化的食用载体或其组合。在另外的方面,经口组合物可制备成糖浆剂或酏剂。糖浆剂或酏剂,并且可包含例如至少一种活性剂、甜味剂、防腐剂、芳香剂、染料、防腐剂,或其组合。
在某些优选的实施方案中,经口组合物可包含一种或更多种黏合剂、赋形剂、崩解剂、润滑剂、芳香剂,及其组合。在某些实施方案中,组合物可包含以下中的一种或更多种:黏合剂,例如如黄蓍胶(gum tragacanth)、阿拉伯胶、玉米淀粉、明胶,或其组合;赋形剂,例如磷酸二钙、甘露醇、乳糖、淀粉、硬脂酸镁、糖精钠、纤维素、碳酸镁,或其组合;崩解剂,例如如玉米淀粉、马铃薯淀粉、海藻酸或其组合;润滑剂,例如如硬脂酸镁;甜味剂,例如如蔗糖、乳糖、糖精或其组合;芳香剂,例如如薄荷、冬青油、樱桃芳香剂、橙子芳香剂等;或前述物质其的组合。当剂量单位形式是胶囊时,其除了上述类型的材料之外可包含载体(例如液体载体)。多种其他材料可作为涂层存在或以其他方式改变剂量单位的物理形式。例如,片剂、丸剂或胶囊可用虫胶(shellac)、糖或二者涂层。
适用于其他施用方式的另外的制剂包括栓剂。栓剂是具有多种重量和形状的固体剂型,通常包含药物,用于插入直肠、阴道或尿道。插入之后,栓剂软化,融化或溶解在腔液中。一般来说,对于栓剂,传统载体可包括,例如聚亚烷基二醇、甘油三酯或其组合。在某些实施方案中,栓剂可由包含例如约0.5%至10%,并且优选约1%至约2%的活性成分的混合物形成。
通过将所需量的活性化合物并入到具有上文所列的多种其他成分的合适的溶剂中,随后无菌过滤来制备无菌可注射溶液。通常,通过将多种经灭菌活性成分并入包含基本分散介质(basic dispersion medium)和/或其他成分的无菌载体中来制备分散体。在用于制备无菌可注射溶液、混悬剂或乳剂的无菌粉末的情况下,优选的制备方法是真空干燥或冷冻干燥技术,这由其经先前无菌过滤的液体介质产生活性成分加任何另外期望成分的粉末。如果必要的话,液体介质应被合适地缓冲,并且在用足够的盐水或葡萄糖注射之前先用液体稀释剂实现等张。还预期了用于直接注射的高度浓缩组合物的制剂,其中预期使用DMSO作为溶剂以实现极其迅速的渗透,从而使高浓度的活性剂递送至小区域。
组合物在制造和储存条件下必须稳定,并且防止微生物(例如细菌和真菌)的污染作用。将理解,内毒素污染应在安全水平下保持最低,例如小于0.5ng/mg蛋白质。
在一些特定的实施方案中,通过在组合物中使用延迟吸收的试剂(例如如单硬脂酸铝、明胶或其组合),可以实现可注射组合物的延长吸收。
IV.组合治疗
为了提高本发明实施方案的核酸、多肽或纳米颗粒复合物的有效性,可期望将这些组合物与有效治疗目的疾病的其他药剂组合。
作为非限制性实例,可使用本发明实施方案的TUSC2治疗剂和/或免疫检查点抑制剂以及其他抗癌剂来实现癌症的治疗。“抗癌”剂能够负面地影响对象中的癌症,例如通过杀伤癌细胞、诱导癌细胞的凋亡、降低癌细胞的生长速率、降低转移的发生率或数量、降低肿瘤尺寸、抑制肿瘤生长、降低向肿瘤或癌细胞的血液供应、促进针对癌细胞或肿瘤的免疫应答、预防或抑制癌症的进展或提高患有癌症之对象的寿命。更一般地,这些其他组合物将以有效杀伤或抑制细胞增殖的组合量提供。该过程可涉及使细胞与抗癌肽或纳米颗粒复合物和药剂或更多种因子同时接触。这可通过使细胞与包含两种药剂的单一组合物或药理学制剂接触或者通过使细胞与两种不同的组合物或制剂同时接触来实现,其中一种组合物包含抗癌肽或纳米颗粒复合物而另一种包含第二药剂。在一些特定的实施方案中,抗癌肽可以是一种药剂,并且抗癌纳米颗粒复合物可以是其他药剂。
用抗癌肽或纳米颗粒-复合物的治疗可以在其他药剂治疗之前或之后进行,间隔为数分钟至数周。在其中其他药剂和抗癌肽或纳米颗粒复合物分别施加于细胞的实施方案中,通常将确保在每次递送的时间之间的有效时段没有超出,以使得药剂和抗癌肽或纳米颗粒复合物仍然能够对细胞发挥有利的组合作用。在这样的情况下,预期可在彼此约12至24小时内并且更优选地在彼此约6至12小时内使细胞与这两种形式接触。在一些情况下,可期望显著延长治疗的时间段,其中在各次施用之间间隔数天(例如,2、3、4、5、6或7天)至数周(例如,1、2、3、4、5、6、7或8周)。
同样,在某些方面,TUSC2治疗与免疫检查点抑制剂结合施用。可使用多种组合,其中TUSC2治疗是“A”并且免疫检查点抑制剂是“B”:
在某些实施方案中,向对象施用本发明实施方案的TUSC2治疗和/或免疫检查点抑制剂将遵循用于施用化学治疗剂的一般方案,同时考虑到载体的毒性(如果有的话)。预计可按需要重复治疗周期。还预期可将多种标准治疗以及手术干预与所述的过度增殖细胞治疗结合使用。
a.化学治疗
癌症治疗还包括多种组合治疗。在一些方面,实施方案的TUSC2治疗剂和/或免疫检查点抑制剂与化学治疗剂结合施用(或配制)。例如,在一些方面,化学治疗剂是蛋白激酶抑制剂,例如EGFR、VEGFR、AKT、Erb1、Erb2、ErbB、Syk、Bcr-Abl、JAK、Src、GSK-3、PI3K、Ras、Raf、MAPK、MAPKK、mTOR、c-Kit、eph受体或BRAF抑制剂。蛋白激酶抑制剂的非限制性实例包括阿法替尼、阿西替尼、贝伐单抗、博舒替尼、西妥昔单抗、克唑替尼、达沙替尼、厄洛替尼、福他替尼(Fostamatinib)、吉非替尼、伊马替尼、拉帕替尼、乐伐替尼、木利替尼、尼洛替尼、帕尼单抗、帕唑帕尼、哌加他尼、兰尼单抗、鲁索替尼、塞卡替尼、索拉非尼、舒尼替尼、曲妥珠单抗、凡德他尼、AP23451、维莫非尼、MK-2206、GSK690693、A-443654、VQD-002、米替福新、哌立福辛、CAL101、PX-866、LY294002、雷帕霉素、坦罗莫司、依维莫司、地磷莫司、Alvocidib、金雀异黄素、司美替尼、AZD-6244、瓦他拉尼、P1446A-05、AG-024322、ZD1839、P276-00、GW572016或其混合物。
另外的组合化学治疗包括例如:烷化剂类,例如噻替派和环磷酰胺;烷基磺酸酯类,例如白消安、英丙舒凡和哌泊舒凡;氮杂环丙烷类,例如苯佐替哌(benzodopa)、卡波醌、美妥替哌(meturedopa)和乌瑞替派(uredopa);乙撑亚胺类(ethylenimines)和甲基蜜胺类,包括六甲蜜胺(altretamine)、三乙撑蜜胺(triethylenemelamine)、三乙撑磷酰胺(trietylenephosphoramide)、三乙撑硫代磷酰胺(triethiylenethiophosphoramide)和三甲蜜胺;番荔枝内酯类(acetogenins)(尤其是布拉他辛和布拉他辛酮);喜树碱类(包括合成的类似物拓扑替康);苔藓虫素(bryostatin);卡利他汀(callystatin);CC-1065(包括其阿多来新、卡折来新和比折来新合成类似物);念珠藻素(特别是念珠藻素1和念珠藻素8);尾海兔素;倍癌霉素(包括合成类似物KW-2189和CB1-TM1);五加素;水鬼蕉碱;匍枝珊瑚醇类;海绵抑制素;氮芥类,例如苯丁酸氮芥、萘氮芥、氯磷酰胺、雌莫司汀、异环磷酰胺、氮芥、盐酸甲氧氮芥、美法仑、新恩比兴、苯芥胆甾醇、泼尼莫司汀、曲磷胺、尿嘧啶氮芥;亚硝基脲类,例如卡莫司汀、氯脲霉素、福莫司汀、洛莫司汀、尼莫司汀和雷莫司汀;抗生素,例如烯二炔类抗生素(例如,加利车霉素,尤其是加利车霉素γ1I和加利车霉素ωI1;达因霉素,包括达因霉素A;二膦酸盐类,例如氯膦酸盐;埃斯培拉霉素类;以及新制癌菌素发色团和相关色蛋白烯二炔抗生素发色团、阿克拉霉素、放线菌素、安曲霉素、重氮丝氨酸、博来霉素、放线菌素C(cactinomycin)、卡柔比星、洋红霉素、嗜癌菌素、色霉素、更生霉素、柔红霉素、地托比星、6-重氮-5-氧代-L-正亮氨酸、多柔比星(包括吗啉代-多柔比星、氰基吗啉代-多柔比星、2-吡咯啉基-多柔比星和脱氧多柔比星)、表柔比星、依索比星、伊达比星、麻西罗霉素、丝裂霉素类(例如丝裂霉素C)、霉酚酸、诺加霉素、橄榄霉素类、培洛霉素、泼非霉素、嘌呤霉素、三铁阿霉素、罗多比星、链黑菌素、链脲霉素、杀结核菌素、乌苯美司、净司他丁、佐柔比星;抗代谢物类,例如甲氨蝶呤和5-氟脲嘧啶(5-FU);叶酸类似物,例如二甲叶酸、蝶罗呤、三甲曲沙;嘌呤类似物,例如氟达拉滨、6-巯基嘌呤、硫咪嘌呤、硫鸟嘌呤;嘧啶类似物,例如安西他滨、阿扎胞苷、6-氮尿苷、卡莫氟、阿糖胞苷、二脱氧尿苷、去氧氟尿苷、依诺他滨、氟尿苷;雄激素,例如卡鲁睾酮、丙酸屈他雄酮、环硫雄醇、美雄烷、睾内酯;抗肾上腺类,例如米托坦、曲洛司坦;叶酸补充剂,例如亚叶酸;醋葡醛内酯;醛磷酰胺糖苷;氨基乙酰丙酸;恩尿嘧啶;安吖啶;贝斯布西;比生群;依达曲沙;地磷酰胺(defofamine);秋水仙胺;地吖醌;依洛尼塞;依利醋铵;埃博霉素类;依托格鲁;硝酸镓;羟基脲;香菇多糖;氯尼达明;美登木素生物碱类,例如美登素和安丝菌素;米托胍腙;米托蒽醌;莫哌达醇;尼曲吖啶;喷司他丁;蛋氨氮芥(phenamet);吡柔比星;洛索蒽醌;鬼臼酸;2-乙酰肼;丙卡巴肼;PSK多糖复合物;雷佐生;根霉素;西佐喃;锗螺胺(spirogermanium);细交链孢菌酮酸(tenuazonic acid);三亚胺醌;2,2′,2”-三氯三乙胺;单端孢霉烯类(尤其是T-2毒素、疣孢菌素A、漆斑菌素A和蛇形菌素);乌拉坦;长春地辛;达卡巴嗪;甘露莫司汀;二溴甘露醇;二溴卫矛醇;哌泊溴烷;加西托星;阿拉伯糖苷(“Ara-C”);环磷酰胺;紫杉烷类,例如紫杉醇和多西他赛吉西他滨;6-硫鸟嘌呤;巯基嘌呤;铂配位络合物,例如顺铂、奥沙利铂和卡铂;长春碱;铂;依托泊苷(VP-16);异环磷酰胺;米托蒽醌;长春新碱;长春瑞滨;诺消灵(novantrone);替尼泊苷;依达曲沙;道诺霉素;氨基喋呤;希罗达;伊班膦酸盐;伊立替康(例如,CPT-11);拓扑异构酶抑制剂RFS 2000;二氟甲基鸟氨酸(DMFO);类视黄醇,例如视黄酸;卡培他滨、卡铂、丙卡巴肼、普卡霉素、吉西他滨、诺维本、法尼基-蛋白质转移酶抑制剂、反铂,以及上述任意一种的可药用的盐、酸或衍生物。在某些实施方案中,本文中提供的组合物可与吉非替尼组合使用。在另外的实施方案中,可将本发明实施方案与格列卫组合实践(例如,可将约400mg/天至约800mg/天的格列卫施用于患者)。在某些实施方案中,一种或更多种化学治疗剂可与本文中提供的组合物组合使用。
b.放射治疗
造成DNA损伤并且已被广泛使用的其他因素包括通常已知的γ-射线、X-射线和/或放射性同位素向肿瘤细胞的直接递送。还考虑了其他形式的DNA损伤因素,例如微波和UV辐照。很可能的是,所有的这些因素对DNA、DNA前体、DNA复制和修复以及染色体的组装和维持产生广泛的损伤。X-射线的剂量范围为:日剂量为在延长时间段(3至4周)中的50伦琴至200伦琴,到2000伦琴至6000伦琴的单次剂量。放射性同位素的剂量范围变化很大,并且取决于同位素的半衰期、所发射辐射的强度和类型以及赘生性细胞的摄入。
本文中使用的术语“接触”和“暴露”当应用于细胞时描述将治疗性组合物和化学治疗剂或放射治疗剂递送至靶细胞或与靶细胞直接邻接放置的过程。为了实现细胞杀伤或停滞,将这两种药剂以有效杀伤细胞或阻止细胞分裂的联合量递送至细胞。
c.免疫治疗
一般来说,免疫治疗依赖于使用免疫效应细胞和分子来靶向和破坏癌细胞。免疫效应物可以是例如对肿瘤细胞表面上的一些标志物具有特异性的抗体。抗体可单独充当治疗的效应物,或者其可招募其他细胞来实际实现细胞杀伤。抗体也可与药物或毒素(化学治疗剂、放射性核素、蓖麻毒蛋白A链、霍乱毒素、百日咳毒素等)缀合并且仅充当靶向剂。或者,效应物可为携带直接或间接与肿瘤细胞靶标相互作用之表面分子的淋巴细胞。多种效应细胞包括细胞毒性T细胞和NK细胞。
因此,免疫治疗可与本发明实施方案的TUSC2治疗结合,作为组合治疗的一部分。下面讨论组合治疗的一般方法。通常,肿瘤细胞必须具有适用于靶向(即,不存在于大多数其他细胞上)的一些标志物。存在许多肿瘤标志物,并且这些肿瘤标志物中的任何一种可能适于本发明实施方案的上下文中的靶向。常见的肿瘤标志物包括癌胚抗原、前列腺特异性抗原、泌尿系统肿瘤相关抗原(urinary tumor associated antigen)、胎儿抗原、酪氨酸酶(p97)、gp68、TAG-72、HMFG、唾液酸路易斯抗原、MucA、MucB、PLAP、雌激素受体、层黏连蛋白受体、erb B和p155。
d.基因治疗
在另一个实施方案中,二级治疗是基因治疗,其中治疗性多核苷酸在治疗组合物之前、之后或与之同时施用。用于基因产物的表达的病毒载体在本领域中是公知的,并且包括真核表达系统,例如腺病毒、腺相关病毒、逆转录病毒、疱疹病毒、慢病毒、痘病毒(包括痘苗病毒)和乳头状瘤病毒(包括SV40)。或者,表达构建体的施用可以用基于脂质的载体(例如脂质体或DOTAP:胆固醇囊泡)来完成。所有这些方法在本领域中是公知的(参见,例如Sambrook等,1989;Ausubel等,1998;Ausubel,1996)。
编码以下基因产物中的任一个的载体的递送将对靶组织具有组合的抗过度增殖作用。多种蛋白质包含在本发明实施方案中,其中一些描述如下。
i.细胞增殖的抑制剂
如上所述,肿瘤抑制癌基因具有抑制过度细胞增殖的功能。这些基因的失活破坏了它们的抑制活性,导致不受调节的增殖。
可用作根据本发明实施方案的二级治疗的基因包括p53、p16、Rb、APC、DCC、NF-1、NF-2、WT-1、MEN-I、MEN-II、zacl、p73、VHL、MMAC1/PTEN、DBCCR-1、FCC、rsk-3、P27、P27/P16融合体、p21/P27融合体、抗血栓形成基因(例如,COX-1、TFPI)、PGS、Dp、E2F、ras、myc、neu、raf、erb、fms、trk,ret、gsp、hst、abl、E1A、p300、涉及血管生成的基因(例如,VEGF、FGF、血小板反应蛋白、BAI-1、GDAIF,或其受体)、MCC和表IV中列出的其他基因。
ii.程序性细胞死亡的调节因子
细胞凋亡或程序性细胞死亡是正常胚胎发育、维持成体组织内的稳态和抑制癌发生的必需过程(Kerr等,1972)。已经证明了Bcl-2蛋白家族和ICE样蛋白酶都是其他系统中细胞凋亡的重要调节因子和效应因子。被发现与滤泡性淋巴瘤相关的Bcl-2蛋白在控制细胞凋亡和提高细胞存活方面发挥重要作用,以响应多种凋亡刺激(Bakhshi等,1985;Cleary和Sklar,Proc.Nat'l.Acad.Sci.USA,82(21):7439-43,1985;Cleary等,1986;Tsujimoto等,1985;Tsujimoto和Croce,1986)。现在认识到演变上保守的Bcl-2蛋白是可归类为死亡激动剂或死亡拮抗剂的相关蛋白的家族的成员。
在Bcl-2的发现之后,已经表明Bcl-2发挥抑制由多种刺激引发的细胞死亡的作用。此外,现在明显的是,存在共有共同结构和序列同源性的Bcl2细胞死亡调节蛋白的家族。已经显示出这些不同的家族成员具有与Bcl-2(例如,BclXL,、Bclw、BclS、Mcl-1、A1、Bfl-1)类似的功能或抵消Bcl-2功能并促进细胞死亡(例如,Bax、Bak、Bik、Bim、Bid、Bad、Harakiri)。
e.手术
约60%的癌症患者经受某类型的手术,其包括预防性、诊断性或分期性、治愈性和姑息性手术。治愈性手术是可与其他疗法(例如,本文提供的治疗、化学疗法、放射疗法、激素疗法、基因疗法、免疫疗法和/或替代疗法)结合使用的癌症治疗。
治愈性手术包括切除,其中物理性移除、切掉和/或破坏所有或部分癌组织。肿瘤切除是指物理性移除至少一部分肿瘤。除肿瘤切除之外,通过手术的治疗包括激光手术、冷冻手术、电手术和微观控制手术(Mohs手术)。还预期本实施方案可与浅表癌、初癌或伴随量的正常组织的移除结合使用。
在切除部分或所有的癌细胞、组织或肿瘤后,在体内可形成腔。可通过灌注、直接注射或对该区域局部施用额外的抗癌疗法来实现治疗。这种治疗可例如每1、2、3、4、5、6或7天进行重复,或者每1、2、3、4和5周进行重复,或者每1、2、3、4、5、6、7、8、9、10、11或12个月进行重复。这些治疗也可使用不同的剂量。
f.抗炎剂
在某些方面,TUSC2治疗和/或免疫检查点抑制剂与抗炎剂结合施用。本文所限定的抗炎剂是指已知或怀疑有益于治疗或预防对象中的炎症的药剂。皮质类固醇是抗炎剂的主要类型。皮质类固醇可以是短期、中期或长期作用的,并且可以以多种方法递送。在本发明实施方案中预期的皮质的非限制性列表包括经口皮质类固醇,例如:可的松、氢化可的松、泼尼松和地塞米松。
抗炎剂的另一类主要类型是非甾体抗炎剂。非甾体抗炎剂包括用于治疗炎症和疼痛的一类药物。这类药物的确切作用方式是未知的。这类药剂的成员的实例包括但不限于布洛芬、酮洛芬、氟比洛芬、萘丁美酮、吡罗昔康、萘普生、双氯芬酸、吲哚美辛、舒林酸、托美丁、依托度酸、氟芬那酸、二氟尼柳、奥沙普秦、罗非昔布和塞来昔布。本领域的普通技术人员将熟悉这些药剂。此类中包括水杨酸盐类和水杨酸盐类的衍生物,例如乙酰水杨酸、水杨酸钠、水杨酸胆碱、水杨酸胆碱镁和二氟尼柳。
其他抗炎剂包括抗风湿剂,例如金盐(例如,硫代苹果酸金钠、硫金代葡萄糖和金诺芬)、抗风湿剂(例如,氯喹、羟氯喹和青霉胺)、抗组胺剂(例如,苯海拉明、氯苯那敏、氯马斯汀、羟嗪和曲普利啶)和免疫抑制剂(例如,氨甲蝶呤、氮芥、环磷酰胺、苯丁酸氮芥、环孢菌素和硫唑嘌呤)。本发明实施方案所预期的其他免疫抑制剂是他克莫司和依维莫司。他克莫司抑制与T细胞活化相关的白介素-2产生,抑制细胞毒性T细胞的分化和增殖。如今,它被全世界公认为免疫抑制剂治疗的基石。本领域的普通技术人员将熟悉这些药剂和这类药剂的其他成员,以及这些药剂的作用机理和使用这些药剂的适应症。
g.其他药剂
预期其他药剂可与本文中提供的组合物组合使用以提高治疗的治疗效力。这些另外的药剂包括免疫调节剂、影响细胞表面受体和GAP连接的上调的药剂、细胞抑制剂和分化剂、细胞黏附抑制剂或提高过度增殖细胞对凋亡诱导剂的敏感性的药剂。免疫调节剂包括肿瘤坏死因子;干扰素α、β和γ;IL-2和其他细胞因子;F42K和其他细胞因子类似物;或MIP-1、MIP-1β、MCP-1、RANTES和其他趋化因子。还预期细胞表面受体或其配体(例如Fas/Fas配体、DR4或DR5/TRAIL)的上调将通过建立对过度增殖细胞的自分泌或旁分泌效应而增强本文中提供的组合物的凋亡诱导能力。通过升高GAP连接数来提高细胞间信号传导可提高对邻近过度增殖细胞群的抗过度增殖作用。在另外的实施方案中,细胞抑制剂或分化剂可以与本文中提供的组合物组合使用以提高治疗的抗过度增殖效力。预期细胞黏附抑制剂提高本发明的效力。细胞黏附抑制剂的实例是黏着斑激酶(FAK)抑制剂和洛伐他汀。还预期可以将提高过度增殖细胞对凋亡的敏感性的其他药剂(例如抗体c225)与本文中提供的组合物组合使用以提高治疗效力。
在某些实施方案中,激素治疗也可与本发明实施方案结合使用或与先前描述的任何其他癌症治疗组合使用。激素的使用可用于治疗某些癌症(例如乳腺癌、前列腺癌、卵巢癌或宫颈癌)以降低某些激素(例如睾酮或雌激素)的水平或阻断其作用。这种治疗通常作为治疗选择或为降低转移风险而与至少一种其他癌症治疗组合使用。
M实施例
包括以下实施例以说明本发明的一些优选实施方案。本领域技术人员应理解,以下实施例中公开的技术表示发明人发现的在本发明的实践中运行良好的技术,并因此可以认为构成用于其实施的优选模式。然而,根据本公开内容,本领域技术人员应理解,在不脱离本发明的精神和范围的情况下,可以对所公开的具体实施方案中进行许多改变,并且仍然获得相似或类似的结果。
实施例1-TUSC2治疗与免疫检查点抑制剂组合
用TUSC2和抗PD1组合治疗有效地抑制在G12VKras突变体同基因肺皮下模型中的肿瘤生长:在C57BL/6小鼠皮下植入具有Kras G12V突变和低水平的TUSC2表达的鼠肺癌细胞系CMT/167-萤光素酶。每组分配10只小鼠:DOTAP:胆固醇(DC)-空载体/同种型;抗PD1抗体;DC-TUSC2纳米颗粒;和DC-TUSC2纳米颗粒+抗PD1抗体。随机化的TUSC2(i.v.)和抗PD1(i.p.)的顺序治疗示于图1A中。没有伴随着组合治疗的毒性。分别用卡尺和IVIS成像测量肿瘤体积和生物发光强度。CMT/167细胞中PD-L1的表达为23.7%(图1B)。抗PD1显示出抑制肿瘤生长的有限效力,而TUSC2显著抑制肿瘤生长(图1C)。该组合通过TUSC2进一步增强了肿瘤的消退。同种型对照、抗PD1、TUSC2和TUSC2+抗PD1的平均体积分别为800mm3、600mm3、300mm3和180mm3(*P<0.05;**P<0.01;并且***p<0.001)。将肿瘤中的生物发光强度测量为每秒总通量的IVS成像也显示了组合的效力(图1D至E)。TUSC2与抗PD1之间的协作效应的后验概率大于99%。这些结果表明,在该模型中,TUSC2与抗PDl协同作用以减小肿瘤生长。
用TUSC2和抗PD1组合治疗提高了NK和CD8+T细胞的密度,并抑制调节性细胞:为了描述TUSC2与抗PD1组合的免疫影响,使用十色组流式细胞术对外周血白细胞(PBL)和脾细胞中的主要免疫群体进行分析。在无肿瘤小鼠中静脉内递送TUSC2纳米囊泡对外周NK、B和T细胞的影响示于图2A中。在无肿瘤小鼠中TUSC2和TUSC2+抗PD1之间没有差异。用于流式细胞术分析的设门策略示于图1的补充中。肿瘤细胞接种之后,发现TUSC2显著且适度地分别诱导了NK和CD8+T细胞的密度(P<0.001和p<0.05),同时伴随着表达PD1、CTLA4和Tim3的B细胞、MDSC、Treg、T细胞显著降低(图2B至E)。抗PD1对NK、T和B细胞没有明显的作用,但减少了表达PD1、CTLA4和Tim3的MDSC、Treg和T细胞。组合治疗与单独的TUSC2具有相同的效果。相对于Treg,组合治疗的最大差异是提高了NK细胞相对于MDSC和CD8+T细胞的比(p<0.001)(图2F)。综上所述,这些结果表明TUSC2-抗PD1协同作用可能与NK和CD8+T细胞扩增的提高有关。
用TUSC2和抗PD1组合治疗增强了肿瘤浸润NK和CD+8T细胞:为了确定TUSC2+抗PD1治疗是否与更密集的肿瘤免疫细胞浸润有关,使用Vectra高通量病理系统对免疫浸润进行分析,所述系统覆盖了每个肿瘤区域的25%(N=5个肿瘤/每个治疗组)。将整个皮下肿瘤均匀切除用于处理,并且考虑到不同治疗组之间不同的肿瘤尺寸,分析来自每个肿瘤的数个切片以消除任何潜在的采样偏差。考虑染色强度并结合阳性细胞百分比,使用H评分值。当与对照或抗PD1相比时,该组合使肿瘤内的CD8+T细胞密度分别提高10倍和3倍(P<0.0001;图3A)。TUSC2组的CD8+T浸润低于组合,但不显著。活化的NK细胞的浸润在用TUSC2治疗的肿瘤中最高(p<0.0001),随后是组合(p<0.0001)(图3A)。与TUSC2或该组合相比,抗PD1略微提高了NK浸润。相反,TUSC2和TUSC2+抗PD1显著抑制肿瘤浸润的Foxp3(由Treg表达的标志物)阳性T细胞(p<0.0001),以及带有肿瘤抑制性粒细胞标志物1(Gr-1)的MDSC(p<0.0001)。虽然抗PD1略微降低了Foxp3密度(p=0.18),但它对GR1没有影响。这些结果表明TUSC2和该组合改变了肿瘤免疫微环境。
用TUSC2和抗PD1的组合治疗增强了与NK细胞和T淋巴细胞相关的趋化因子表达:使用Nanostring技术分析血清趋化因子的表达谱。在暴露于TUSC2和组合之后,发现一组趋化因子基因的上调与T淋巴细胞和NK细胞的迁移有关(图3B)。通过CCR5识别参与NK细胞迁移的CcL3和CcL4的表达提高多于两倍,而与CCR7受体相互作用并将T细胞和树突细胞募集到肿瘤的CcL21a和CcL19(Viola等,2012;Griffith等,2014)与未经治疗的对照相比,提高了多于四倍。与对照组相比,通过TUSC2和TUSC2+抗PD1治疗也提高了CcL4和CcL5血清趋化因子水平(图3C)。
NK或CD8+T细胞的耗竭分别完全和部分消除了该组合的抗肿瘤作用:组合治疗之后NK和CD+8二者的密度上调的发现强烈提示了CD8+T细胞和NK细胞调节TUSC2+抗PD1诱导的肿瘤消退。为了确认该假设,通过腹膜内注射抗NK1.1或抗CD8+T细胞抗体,使携带CMT167肿瘤的小鼠中的NK或CD8+T细胞耗竭(图8、9)。如图4A中所示,通过组合用抗NK1.1抗体的治疗完全消除了肿瘤消退,而用抗CD8+T抗体的治疗使其部分受损(图4B)。此外,NK细胞耗竭消除了TUSC2诱导的肿瘤生长抑制,而CD8+T细胞耗竭没有效果。哪一种耗竭都不会对抗PD1应答产生任何影响。这些研究结果表明,虽然CD8+T细胞可能有助于对抗PD1的TUSC2增强的敏感性,但NK细胞对于这种协同作用是必不可少的。
接下来,使用Luminex测定分析血清细胞因子,发现TUSC2和该组合均诱导强烈的Th1介导的免疫应答(对照vs TUSC2:p<0.0001;对照vs组合:p=0.007(图4C),该免疫应答是NK耗竭所消除的影响(TUSC2vs TUSC2/NK1.1:p=0.008;组合vs组合/NK1.1:p=0.0009),这表明NK细胞在诱导Th1介导的对TUSC2和组合的免疫应答中很重要。但是,在有或没有NK耗竭的情况下,这两个治疗组的Th1/Th2比没有显著差异。与它们未经治疗或经抗PD1治疗的对应物相比,TUSC2+抗PD1治疗促使IL-15(p=0.0001)和IL-18(p<0.0001)细胞因子的水平升高(图4D)。在TUSC2和组合组中IL-15被诱导至相同水平,而在TUSC2中的IL-18水平显著高于组合中的IL-18水平。当NK细胞耗竭时,IL-15的水平(对照vs TUSC2:p=0.03)和IL-18(对照组vs TUSC2:p=0.0005)显著降低。在NK耗竭或没有耗竭的情况下,TUSC2和组合之间的IL-18水平存在显著差异,但对于IL-15则没有。最后,使用qPCR和Nanostring技术的分选的NK细胞和肿瘤组织的表达谱显示TUSC2治疗中的IL-15R和IL-18R的表达显著高于其未经治疗和经抗PD1治疗的对应物中的IL-15R和IL-18R的表达(分别地,p=0.01和p=0.001;图4E、F)。
用TUSC2和抗PD1的组合治疗增强了同基因G12D Kras-突变体肺转移模型的存活:在使用129Sv小鼠的第二Kras转移模型中评价TUSC2+抗PD1的效力,所述小鼠静脉内接种有具有K-rasG12D突变的344SQ-萤光素酶肺癌细胞。344SQ细胞中的PD-L1表达水平为仅4.5%(图5A)。顺序治疗策略示于图5B中。治疗组与之前的模型类似,其中添加两组,抗PD1与抗CTLA4的组合以及TUSC2与抗PD1和抗CTLA4的组合。前者组合用于该实验,因为与单独的每种药物相比,报道了增强的临床效力(Larkin等,2015)。与未经治疗、抗PD1和抗PD1+抗CTLA4治疗组相比,TUSC2显著提高了存活(TUSC2vs对照:p<0.0001;TUSC2vs抗PD1:p<0.001;TUSC2vs抗PD1+抗CTLA4:p<0.001)(图5C)。当TUSC2与抗PD1组合时,存活显著延长(组合vs对照:p<0.0001;组合vs抗PD1:p<0.001;组合vs TUSC2:p=0.024)。将TUSC2与抗PD1和抗CTLA4组合比TUSC2+抗PD1治疗延长存活数天。肿瘤的生物发光成像支持这些发现(图5D)。图5E显示在第2周给予TUSC2+抗PD1的情况下肺中肿瘤结节的明显清除。这些结果证实了TUSC2+抗PD1组合的效力,并且表明TUSC2与双检查点阻断(抗PD1和抗CTLA4)组合具有转化价值。
使用单一细胞分析的免疫细胞浸润分析显示,与对照或与抗CTLA4组合的抗PD1治疗组相比,通过TUSC2的NK细胞浸润更高(p<0.001)(图5F)。TUSC2+抗PD1或TUSC2+抗PD1+抗CTLA4的作用略高于TUSC2的作用。相反,Treg和MDSC细胞浸润被抗PD1显著抑制(p=0.004;p=0.0003),通过TUSC2和组合进一步增强了该作用(图5G和5H)。这些结果与在CMT167皮下肿瘤模型的评价中观察到的结果一致(图2)。
TUSC2与抗PD1组合改变了肿瘤微环境中的免疫基因表达谱:为了鉴定在TUSC2+抗PD1组合中差异表达的特异性免疫基因,使用由770个小鼠免疫基因组成的小鼠泛癌组对来自肿瘤样品的RNA进行数字多路复用分析,所述小鼠免疫基因覆盖具有40个持家对照(NanoStringTechnologies Inc.)的适应性和先天性应答二者。应用具有错误发现率(q<0.05)校正的Welch′s t检验得出治疗组之间统计学上显著的基因表达差异。p值<0.05被认为是显著的。使用火山图和热图来使结果可视化(图6A、B)。因为TUSC2添加增强了对抗PD1治疗的应答,所以在抗PD1和TUSC2+抗PD1组之间进行成对比较。在所有其他组之间也进行了成对比较。首先,发现6个基因簇在组合组中显著上调。这包括Cdld2、Ltf、Klra21、H60a、Tnfsf18和Bcl6。发现另一簇显著下调,其由Egr3、Cd46、Ncr1、Klra5、Ccl1、Il12rb2和Cd59b组成(图6B)。所有这些基因对于NK和CD8+T细胞调节都很重要(Deng等,2013;Shevach和Stephens,2006;Orr等,2009)。组合治疗还上调了肿瘤微环境中与T细胞介导的抗肿瘤功能相关的基因的表达(图6D至F)。这些结果支持NK和CD8+T免疫分析和肿瘤浸润数据(图2至3)。
实施例2-材料和方法
细胞培养和试剂:KRasG12/CMT167-luc和K-RasG12D/344SQ-luc细胞由AlanFields博士(Mayo Clinic),FrankR.Jirik博士(University ofCalgary)友情提供。细胞在补充有10%胎牛血清(Atlanta Biological,GA)和1%青霉素和链霉素(life sciencetechnologies)的Dulbecco改良Eagle培养基中培养。同种型,抗PD1、抗CTLA4、InVivoPlus抗NK1.1(克隆PK136)和抗CD8+T(克隆2.43)抗小鼠单克隆抗体均购自Bio X Cell(WestLebanon,NH)。DOTAP和胆固醇购自Avanti Polar Lipids(Albaster,AL)。先前描述了DC-TUSC2的合成和制备(Ito等,2004)。
动物研究:所有动物程序均由德克萨斯大学MD安德森癌症中心的动物护理和使用委员会(Animal Care and Use Committee of The University of Texas MD AndersonCancer Center)审查和批准。对于CMT167-1uc同基因模型,将6至8周龄雌性C57BL/6-Elite小鼠(Charles River Laboratories,Houston,TX)在右胁皮下注射1×106个CMT167-luc细胞,并如下随机分为治疗组,每组10只小鼠:对照(空载体纳米囊泡、同种型抗体)、抗PD1、TUSC2纳米囊泡和TUSC2+抗PD1。简言之,每48小时静脉内注射25μg TUSC2,共3个周期,每4天腹膜内(i.p.)注射0.25mg抗PD1抗体,共3个周期。根据公式1/2(长度×宽度2)计算肿瘤体积。在肿瘤细胞注射之后3至4周对小鼠进行安乐死,并收获肿瘤和脾。对于344SQ转移模型,向6至8周龄雌性129/Sv小鼠静脉内注射100,000个344SQ-luc细胞。治疗组/各10只,治疗组为:对照(空载体纳米囊泡、同种型抗体)、抗PD1、TUSC2、抗CTLA4、TUSC2+抗PD1、抗PD1+抗CTLA4和TUSC2+抗PD1+抗CTLA4。对于这两种模型,常规监测动物并使用IVIS对肿瘤进行成像。所有治疗和测量均为双盲。对于免疫分型分析,在肿瘤细胞注射之后2周处死动物,收获肺并通过心脏穿刺收集外周血。
NK或CD8+T细胞的耗竭:为了耗竭荷瘤CMT167小鼠的NK细胞或CD8+T细胞,在皮下接种肿瘤细胞之后的第0天开始,每3天向小鼠注射中和单克隆抗体抗NK1.1(克隆PK136)或抗CD8+T(克隆2.43)抗小鼠单克隆抗体(100μg,i.p.),共4个周期。通过流式细胞术分析脾细胞监测NK或CD8+T细胞耗竭状态。测量肿瘤体积并用IVIS对肿瘤生物发光强度进行定量。
多色流式细胞术:分离PBL并根据流式细胞术的标准方案对细胞进行染色。使用Gallios流式细胞仪研究系统(Beckman Coulter,Brea,CA)开发并优化多色组。小鼠抗体购自BioLegend(San Diego,CA)。用荧光激活细胞分选染色缓冲液洗涤单一细胞混悬液,将其与小鼠Fc受体结合抑制剂孵育10分钟,并用指定的抗体染色。使用10版本的FlowJo软件(FlowJo,Ashland,OR)对数据进行分析。
免疫组织化学:将从CMT167收获的肿瘤固定在10%多聚甲醛中,并用抗CD8、抗Foxp3、抗Gr-1和抗NKp46小鼠抗体对8μm福尔马林固定的石蜡包埋组织切片进行染色。所有免疫组织化学分析均在MD安德森Histology Core Laboratory(Smithville,TX)进行。用每种抗体对每组至少五个肿瘤样品进行染色,使用MD安德森的Imaging Core Facility(Houston,TX)的200张载玻片Vectra 3.0自动定量病理成像系统(PerkinElmer,Waltham,MA)进行成像和分析。通过每个细胞产生0至+3的H评分。
定量PCR:使用RNeasy Mini试剂盒(Qiagen,Hilden,Germany)提取总RNA,并使用SuperScript III试剂盒(Invitrogen,Carlsbad,CA)进行逆转录。用SYBR Green PCRMaster Mix(Applied Biosystems,Foster City,CA)进行定量PCR。将相对表达水平归一化,并用ABI Viia7实时PCR系统(Applied Biosystems)测量表达水平。使用制造商描述的比较CT方法进行相对定量。
Luminex测定:为了鉴定血清细胞因子和趋化因子,根据制造商的说明使用Affymetrix(eBioscience)ProcartaPlex 36重免疫测定(Affymetrix,Santa Clara,CA)。将每个治疗组的三个样品一式两份进行分析。简言之,根据制造商的方案制备七份标准品,并将25μL血清样品与指定的抗体包被的珠混合,并在室温下以500rpm摇动孵育2小时。ProcartaPlex Multiplex Immunoassays使用Luminex xMAP(多分析物分析)技术。使用Luminex 200系统(Luminex,Austin,TX)读取板以绘制标准曲线。使用1.0版本的ProcartaPlex Analyst软件来分析数据。
基因表达分析:将使用Qiagen RNeasy Mini试剂盒从治疗组提取的总肿瘤RNA(每个重复三次)提交给Baylor College of Medicine的Genomic Core Facility(Houston,TX),用于进行质量控制和使用NanoString Technology的表达谱分析。NanoString泛癌小鼠免疫分析组使用了与特定免疫细胞类型和免疫细胞功能相关的776个基因进行分析。在MD安德森的Bioinformatics Core Facility对数据进行分析。
统计分析:对于CMT167模型,使用一般线性回归模型来分析肿瘤生长。所有数据均以平均值±SD表示,治疗间差异的统计学显著性通过双因素ANOVA和加尾t检验进行检验;P<0.05被认为是显著的。对于344SQ模型,通过Kaplan-Meier方法估算总存活(overallsurvival,OS)的分布。进行对数秩检验以测试组间存活的差异。当OS被限定为从治疗开始时间到死亡时间的情况下对基于Cox比例风险模型的存活数据进行回归分析。
通过一般线性回归模型对流式细胞术和luminex数据进行统计分析,以比较不同的治疗组。对于免疫组织化学数据,使用一般线性回归模型对治疗组之间的H评分进行统计分析。在每对之间使用SAS中的PROCMIXED程序中的ESTIMATE语句。对于NanoString分析,数据在用于对基因谱和统计分析进行量化之前被归一化。使用阳性对照、持家基因和阴性对照以对样品制备变化、背景噪音和RNA含量变化进行调节。使用线性模型来评估整体治疗效果,并且使用对照物以进行目的成对比较。使用β-均匀混合物(BUM)模型对得到的p值进行建模,以确定错误发现率(FDR)截止值并识别显著差异表达的基因。所有统计分析均使用R统计学软件进行。
***
根据本公开内容,无需过度实验就可以进行和实施本文公开和要求保护的所有方法。尽管已经以一些优选实施方案的方式描述了本发明的组合物和方法,但对于本领域技术人员来说明显的是可改变本文中所述的方法以及所述方法的步骤或步骤顺序而不脱离本发明的概念、精神和范围。更具体地,明显的是,可用化学和生理学二者相关的某些试剂替代本文描述的试剂,同时将获得相同或相似的结果。对于本领域技术人员明显的所有此类相似的替代和改变被视为在由所附权利要求书所限定的本发明的精神、范围和概念内。
参考文献
以下参考文献通过引用特定地并入本文,在某种程度上,其提供了补充本文所列那些的示例性过程或其他细节。
U.S.Patent4,162,282
U.S.Patent4.310.505
U.S.Patent4,533,254
U.S.Patem 4,554,101
U.S.Patent 4,728,575
U.S.Patent 4,728,578
U.S.Patent4,737,323
U.S.Patent 4,921,706
U.S.Pstent 5,030,453
U.S.Patent5,397,987
U.S.Patent 5,855,911
U.S Patent 5,962,016
U.S.PPatent 6,413,544
U.S,Patent 6,610,657
U.S.Patent 6,680,068
U.S.Patent 6,770,291
U.S.Patent 6,770,291
U.S.Patent 7,902,441
U.S.Publn.2004/0208921
U.S.Publn.2006/0251726
U.S.Publn.2007/0092968
U.S.Publn.2009/0023207
U.S.Publn.2011/0052570
Aksentijevich eal.,Human Gene Therapy,7:1111-22,1996.
Arap et al.,Cancer Res.,55(6):1351-1354,1995.
Ausubel et al.,Currenl Protocols in Molecular Biology,John Wiley&Sons,Inc.,New York,N.Y.,1996;1998
Bakhshi et al.,Cell,41(3):899-906,1985.
Ballou et al.,Bioconjugate Chemistry,15:79-86,2004.
Ben-Neriah et al.,Science,233:212-214,1986.
Bishop,Cell,64;235-48,1991.
Blankenberg,Cancer Biology&Therapy,7(10):1525-1532,2008.
Brady and Dodson,Marure,368:692-693,1994,
Buchhagen et al.,Head and Neck,18:529-537,1996.
Butturini et al.,Leukemia Res.,20(6):523-529,1996.
Caldas et al.,Nat.Genet,,8(1):27-32,1994.
Chapman et al.,Nucleic acid Res,19:3979-3986,1991.
Cheng et al.,Cancer Res.,54(21):5547-5551,1994.
Cheng et al,Invest.Radiol.,22(1):47-55,1987.
Clayman et al.,Journal of Clinical Oncology,16:2221-32,1998.
Cleary and Sklar,Proc.Natl.Acad.Sci.USA,82(21):7439-43,1985.
Cleary et al.,J.Exp.Med.,164(1):315-320,1986.
Colledge and Scott,Trends in Cell Biology,9:216-221,1999.
Daly et al.,Oncogene,8:1721-1729,1993.
Deng et al.,Cancer Res.,67:709-17,2007.
Deng et al.,Oncogene,32:4273-83,2013.
Drin et al.,AAPS Pharm,Sci,4(4):1-7,2002.
Du et al.,J.Pept.Res.,51:235-243,1998.
Dubertret et al.,Science,298:1759-1762,2002.
Dwarakanath et al,Biochem.Biophysical Res.Coommun.,325:739-743,2004.
Eggermont et al.,EMBO J.,12:2539-2548,1993.
Ellerby et al.Nature Med,9:1032-1038,1999.
Farhood et al.,Biochim.Biophys.Act,289-295,1995.
Ferrari,Natture Reviews,5:161-171,2005.
Fidler and Ellis,Cell,79(2):185-188,1994.
Folkman and Shing.J.Biol.Chem.,267(16):10931-10934,1992.
Follkman,Nature Med.,1:27-31,1995.
Frangioni,Current Opin.Chem.Biol.,7:626-634,2003.
Gazdar et al.In:Sym.Quant.Biol.,Cold Spring Harbor,59:565-572.1994.
Gazdar et al.,IntL.J.Cancer,78:766-774,1998.
Ghosh and Bachhawat,In:Liver Diseases,Targeted Diagnosis and TherapyUsing Specific Receptors and Ligands,Wu et al.(Eds.),Mareel Dekker.NY,87-104,1991.
Goodwin et al.,J.Biol Chem.,267:16330-16334,1992.
Gorunova et al,Genes Chrom.Cancer,23:81-99,1998.
Great Britain Appln.2193095 A
Griffith et al.,Annual review of immunology,32:659-702,2014.
Gupta et al.,Biomaterials,26:3995-4021,2005,
Gupta et al.,Biomaterials.26:3995-4021,2005.
Gupta et al.,Bionunterials.26:3995-4021,2005.
Gupta,IEEE Trans.Nanobioscience.,3:66-73,2004.
Hanahan and Folkman,Cell,86(3):353-364,1996.
Hantschel et al.,Cell,112:845-857,2003.
Hollsteiln et al.,Science,253(5015):49-53,1991.
Hope et al.,1985
Horowitz,In:MR1 Physics for Radiologists:A Visual Approach,1995
Hughson et al.,Cancer Genet.Cytogenet.106:93-104,1998.
Hussussian et al.,Nat.Genet.,8(1):15-21,1994.
Hvalby et al.,Proc.Natl.Acad.Sci.USΛ,91:4761-4765,1994.
Ito et al.,Mol Ther.,7:409-18,2003.
Ito et al.,Cancer Gene Ther.,11:733-9,2004.
Ivanova et al,J Pathol,211:591-601,2007.
Jameson et al.,Nature 368:744-746,1994
Ji et al.,Cancer Res.,62:2715-2720,2000.
Ji et al,,Cancer Res.,62:2715-20,2002.
Ji et al.,Future Oncology,1:79-92,2005,
Ji et al.,Journal of Thoracic Oncology.,327-30 10.1097/JTO.0b013e31816bce65,2008.
Johnson et al.,J.Virol.,67:438-445,1993.
Kamb et al.,Nat.Genet.,8(1):23-26,1994.
Kamb et al.,Science,2674:436-440,1994,
Kerr et al.,Br.J.Cancer,26(4):239-257,1972.
Kerr et al.,Br.J.Cancer,26(4):239-257,1972.
Kersemaekers et al.,Intl.J.Cancer,79:411-417,1998.
Kloetzer et al.,Virology,140(2):230-238,1985.
Kohno et al.,Cancer,85:341-347,1999.
Kondo et al.,Oncogene,20:6258-6262,2001.
Kondo et al.,Oncogene,20:6258-6262,2001.
Kyte and Doolittle.J.Mol.Biol.,157(1):105-132,1982.
Lerman et al.,Cancer Res.,60:6116-33,2000.
Lewin et al.,Nat.Biotechnol.,18:410-414,2000.
Lin et al.,Oncogene,20:1873-1881,2001,
Ling et al.,Cancer Res.,63:298-303,2003.
Liposome Technology,Gregoriadis(Ed.),Boca Raton,FL,CRC Press.1984.
Lowe et al.,Nature,2004,432:307-15,2004.
Mabry et al.,In:Lumg Caancer in dhe Genetic Basis of HumanCancer.Vogelstein and Kinzler (Eds.),McGraw Hill.671-679,1998.
Maver et al.,Biochim,Biophys.Acta,858(1):151-168,1986.
Mayhew et al.,Biochim.Biophys.Acta,775(2):169-174,1984.
Mayhew et al.,Methods Enzymol.,149:64-77,1987.
Miehalet et al.,Science,307:53S-544,2005.
Miller et al.,Cancer.47:207-214,1981.
Miller et al.,Oncogene,22:6006-6013,2003.
Minna et al.,In:Cancer:Principles and Practicce of Oncology,5th Ed.,Philadelphia:Lippincott,849-857,1997.
Morawski et al.,Current Opinion Biotech.,16,89-92,2005.
Mori et al.,Cancer Res.,54(13):3396-3397,1994.
Nishihara et al.,Cancer Letter,180(1):55-61,2002.
Nobri et al.,Nature(London),368:753-756,1995.
Obenauer et al.,Nucleic Acids Res.,31(13):3635-3641,2003.
Okamoto et al.Proc.Natl.Acad.Sci.USA,91(23):11045-11049,1994.
Orlow et al,Cancer Res,54(11):2848-2851,1994.
Orlow et al.,Int.J.Oncol.,15(1):17-24,1994.
Orr et al.,The Journal ofexperimen tal nedicine,206:807-17,2009.
O’Quigley J et al.,Biomelrics,46:33-48,1990.
PCT Appln.PCT/US85/01161
PCT Appln.PCT/US89/05040
PCT Appln,WO 02/100435A1
PCT Appln.WO03/015757A1
PCT Appln.WO 04/002453A1
PCT Appln.WO04029213A2
Pure&Appl.Chem.,63(3):427-463,1991.
Ramesh et al.,Mol Ther.,3:337-50,2001,
Remington’s Pharmaceutical Sciences”15th Edition,pages 1035-1038and1570-1580,1990.
Roberts et al.,Adv.Drug Del.Rev.,54(4):459-476,2002.
Rojas et al.,J.Biol.Chem.,271:27456-27461,1996.
Rojas et al.,Nature Biotechnol.,16:370-375,1998.
Roth et al.,Nat Med.,2:985-91,1996.
Roth.Forum,8:368-376,1998.
Roth.Expert Opinion on Biological Therapy,6;55-61,2006.
Sambrook et al.,In:Molecular Cloning:A Laboratory ManMal,2nd Ed.,ColdSpring Harbor Press,Cold Spring Harbor,NY,1989
Schwarze et al.,Science,285:1569-1572,1999.
Schwarze et al.,Trends Cell Biol.,10:290-295,2000.
Sekido et al.,Biochimica.Biophysica.Acta,1378:F21-F59,1998.
Sekido et al.,Oncogene,16:3151-3157,1998.
Sekido et al,Proc.Narl.Acad.Sci.USA,93:4120-4125,1996.
Serrano et al.,Nature,366:704-707,1993,
Serrano et al.,Science,267(5195):249-252,1995.
Sestier et al.,Electrophoresis,19:1220-1226,1998.
Shevach and Stephens,Nature reviews Immunotogy,6:613-8,2006.
Simberg et al.,Human Gene Therapy,16:1087-96,2005.
Simherg et al.,Proceedings of the National A cademy of Sciences,104:932-6,2007.
Spandidos et al.,A nticancer Res.,9(2):383-386,1989.
Stayton et al.,J.Controlled Release,65:203-220,2000.
Sun et al.,Biopolymers,60(1):61-75,2001.
Swisher et al.,J Natl Cancer Inst.,91:763-71,1999.
Templeton,Nature Biotech.,15:647-652,1997.
Templeton,Nature Biotechnology,15:647-652,1997.
Travali et al.,FASEB J.,4(14):3209-3214,1990.
Tsujimoto and Croce,Proc,Nall,Acad.Sci.USA,83(14):5214-5218,1986.
Tsuiimoto et al.,Science,228(4706):1440-1443,1985.
Uno et al.,Cancer Research,64:2969-2976,2004.
Uzawa et al.,Cancer Genel.Cytogenet.,107:125-131,1998.
Viola et al.,Trends in Inmunology.33:496-504,2012.
Virmani et al,Genes Chrom Cancer,21:308-319,1998.
Wang,Oncogene,19(49):5643-5650,2000.
Weinberg,Science,254(5035):1138-1146,1991.
Weinberg,Sience,254:1138-1146,1991.
Wen and Van Euen,Genes and Development,11:2456-2467,1997.
West,Methodsin Molec.Biol.,238:113-122,2004.
Wilhelm et al.,Biomaterials,24:1001-1011,2003.
Wistuba etal.,CancerRes.,57:3154-3158,1997.
Wistuba etal.,Cancer Res.,59:1973-1979,1999.
Wistuba et al.,Oncogene,18:643-650,1999.
Woodring et al.,J.Cellular Science,116(Pt.13):2613-2626,2003.
Zbar et al.,Nature,327:721-724,1987.
Yang et al.,Gene Ther.,4:950-60,1997.
Zhao,Anti-Cancer Agents in Medicinal Chemistry,9:1018-1023,2009.
Claims (39)
1.TUSC2治疗剂和抗PD1抗体在制造用于治疗患有癌症之对象的药物组合中的用途,其中所述对象已经或正在用所述抗PD1抗体进行治疗。
2.权利要求1所述的用途,其中所述治疗还包括施用所述抗PD1抗体。
3.权利要求2所述的用途,其中向所述对象施用所述抗PD1抗体包括在所述TUSC2治疗剂之前施用所述抗PD1抗体。
4.权利要求2所述的用途,其中向所述对象施用所述抗PD1抗体包括在所述TUSC2治疗剂之后或与之同时施用所述抗PD1抗体。
5.权利要求1所述的用途,其中在所述TUSC2治疗剂之前不超过两周内向所述对象施用所述抗PD1抗体。
6.权利要求1所述的用途,其中所述抗PD1抗体是纳武单抗、派姆单抗、匹地利珠单抗、KEYTRUDA®、AMP-514、REGN2810、CT-011、BMS 936559、MPDL328OA或AMP-224。
7.权利要求1所述的用途,其中所述对象已经或正在用第二种免疫检查点抑制剂进行治疗。
8.权利要求7所述的用途,其中所述第二种免疫检查点抑制剂是抗CTL4抗体。
9.权利要求1所述的用途,其中所述TUSC2治疗剂包括TUSC2表达载体。
10.权利要求9所述的用途,其中所述TUSC2表达载体是质粒DNA。
11.权利要求10所述的用途,其中所述质粒是pLJ143/KGB2/FUS1。
12.权利要求9所述的用途,其中在脂质体中提供所述TUSC2表达载体。
13.权利要求12所述的用途,其中所述脂质体是DOTAP:胆固醇脂质体。
14.权利要求13所述的用途,其中所述DOTAP:胆固醇比为1.5:1至1:1.5。
15.权利要求13所述的用途,其中所述DOTAP:胆固醇比为10:9。
16.权利要求13所述的用途,其中所述TUSC2表达载体和DOTAP:胆固醇脂质体以0.01mg/kg至0.10 mg/kg的剂量施用。
17.权利要求1所述的用途,其中所述TUSC2治疗剂施用两次或更多次。
18.权利要求1所述的用途,其中所述治疗还包括施用抗炎剂。
19.权利要求1所述的用途,其中所述TUSC2治疗剂包括TUSC2多肽。
20.权利要求19所述的用途,其中所述TUSC2多肽是经肉豆蔻酰化的。
21.权利要求19所述的用途,其中所述TUSC2多肽包含在纳米颗粒中。
22.权利要求21所述的用途,其中所述纳米颗粒是基于脂质的纳米颗粒、超顺磁性纳米颗粒、纳米壳、半导体纳米晶体、量子点、基于聚合物的纳米颗粒、基于硅的纳米颗粒、基于二氧化硅的纳米颗粒、基于金属的纳米颗粒、富勒烯或纳米管。
23.权利要求1所述的用途,其中所述治疗还包括向所述对象施用另外的抗癌治疗。
24.权利要求23所述的用途,其中所述另外的抗癌治疗是化学治疗、放射治疗、基因治疗、手术、激素治疗、抗血管生成治疗或细胞因子治疗。
25.权利要求24所述的用途,其中所述另外的抗癌治疗是EGFR抑制剂。
26.权利要求1所述的用途,其中所述癌症是口腔癌、口咽癌、鼻咽癌、呼吸系统癌、泌尿生殖系统癌、胃肠癌、中枢或周围神经系统组织癌、内分泌或神经内分泌癌或造血癌、胶质瘤、肉瘤、上皮癌、淋巴瘤、黑素瘤、纤维瘤、脑脊膜瘤、脑癌、肾癌、胆道癌、嗜铬细胞瘤、胰岛细胞癌、利-弗劳梅尼瘤、甲状腺癌、甲状旁腺癌、垂体瘤、肾上腺瘤、成骨肉瘤肿瘤、I型和II型多发性神经内分泌肿瘤、乳腺癌、肺癌、头颈癌、前列腺癌、食管癌、气管癌、肝癌、膀胱癌、胃癌、胰腺癌、卵巢癌、子宫癌、宫颈癌、睾丸癌、结肠癌、直肠癌或皮肤癌。
27.权利要求26所述的用途,其中所述癌症是肺癌。
28.权利要求27所述的用途,其中所述肺癌是非小细胞肺癌。
29.权利要求27所述的用途,其中所述癌症是转移性肺癌。
30.权利要求1所述的用途,其中所述癌症对至少第一化学治疗有抗性。
31.权利要求30所述的用途,其中所述癌症对基于铂的化学治疗有抗性。
32.权利要求2所述的用途,其中施用所述TUSC2治疗剂和所述抗PD1抗体导致所述癌症患者的肿瘤中NK和/或CD8+ T细胞密度提高。
33.权利要求32所述的用途,其中所述CD8+ T细胞密度提高至少3倍。
34.权利要求2所述的用途,其中施用所述TUSC2治疗剂和所述抗PD1抗体导致了CcL3、CcL4、CcL21a和/或CcL19血清水平提高。
35.药盒,其包含TUSC2治疗剂和抗PD1抗体。
36.权利要求25所述的用途,其中所述EGFR抑制剂是酪氨酸激酶抑制剂。
37.权利要求25所述的用途,其中所述EGFR抑制剂是EGFR结合抗体或适配体。
38.权利要求25所述的用途,其中所述EGFR抑制剂是吉非替尼,厄洛替尼、西妥昔单抗、马妥珠单抗、帕尼单抗、AEE788;CI-1033、HKI-272、HKI-357或EKB-569。
39.组合物,其包含治疗癌症之治疗有效量的TUSC2治疗剂和抗PD1抗体。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310535801.7A CN116672456A (zh) | 2016-10-12 | 2017-10-12 | 用于tusc2免疫治疗的方法和组合物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662407329P | 2016-10-12 | 2016-10-12 | |
US62/407,329 | 2016-10-12 | ||
PCT/US2017/056338 WO2018071668A1 (en) | 2016-10-12 | 2017-10-12 | Methods and compositions for tusc2 immunotherapy |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310535801.7A Division CN116672456A (zh) | 2016-10-12 | 2017-10-12 | 用于tusc2免疫治疗的方法和组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110072540A CN110072540A (zh) | 2019-07-30 |
CN110072540B true CN110072540B (zh) | 2023-06-02 |
Family
ID=61906060
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780076886.XA Active CN110072540B (zh) | 2016-10-12 | 2017-10-12 | 用于tusc2免疫治疗的方法和组合物 |
CN202310535801.7A Pending CN116672456A (zh) | 2016-10-12 | 2017-10-12 | 用于tusc2免疫治疗的方法和组合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310535801.7A Pending CN116672456A (zh) | 2016-10-12 | 2017-10-12 | 用于tusc2免疫治疗的方法和组合物 |
Country Status (14)
Country | Link |
---|---|
US (2) | US11278592B2 (zh) |
EP (1) | EP3525809A4 (zh) |
JP (3) | JP7041136B2 (zh) |
KR (1) | KR102661905B1 (zh) |
CN (2) | CN110072540B (zh) |
AU (2) | AU2017342364B2 (zh) |
BR (1) | BR112019007365A2 (zh) |
CA (1) | CA3040458A1 (zh) |
CL (1) | CL2019001002A1 (zh) |
IL (1) | IL265965A (zh) |
MA (1) | MA46542A (zh) |
RU (1) | RU2755903C2 (zh) |
SG (1) | SG11201903283UA (zh) |
WO (1) | WO2018071668A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015166986A1 (ja) | 2014-04-30 | 2015-11-05 | 富士フイルム株式会社 | リポソーム組成物及びその製造方法 |
AU2019288048B2 (en) * | 2018-06-20 | 2022-08-11 | Fujifilm Corporation | Combined medicine comprising gemcitabine-encapsulated liposome composition and immune checkpoint blockade |
CN116121194B (zh) * | 2023-02-27 | 2023-10-24 | 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) | 一种肺癌免疫治疗耐药细胞系及其制备方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007092944A2 (en) * | 2006-02-08 | 2007-08-16 | Introgen Therapeutics, Inc. | Compositions and methods involving gene therapy and proteasome modulation |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4162282A (en) | 1976-04-22 | 1979-07-24 | Coulter Electronics, Inc. | Method for producing uniform particles |
US4310505A (en) | 1979-11-08 | 1982-01-12 | California Institute Of Technology | Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances |
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US4533254A (en) | 1981-04-17 | 1985-08-06 | Biotechnology Development Corporation | Apparatus for forming emulsions |
US5030453A (en) | 1983-03-24 | 1991-07-09 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
US4728575A (en) | 1984-04-27 | 1988-03-01 | Vestar, Inc. | Contrast agents for NMR imaging |
US4921706A (en) | 1984-11-20 | 1990-05-01 | Massachusetts Institute Of Technology | Unilamellar lipid vesicles and method for their formation |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
IL79559A0 (en) | 1986-07-29 | 1986-10-31 | Univ Ramot | Contrast agents for nmr medical imaging |
US4728578A (en) | 1986-08-13 | 1988-03-01 | The Lubrizol Corporation | Compositions containing basic metal salts and/or non-Newtonian colloidal disperse systems and vinyl aromatic containing polymers |
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US5397987A (en) | 1993-03-03 | 1995-03-14 | Rheometrics, Inc. | Method and apparatus for analyzing samples using nuclear magnetic resonance |
CA2144319A1 (en) | 1993-07-09 | 1995-01-19 | George N. Cox | Recombinant ctla4 polypeptides and methods for making the same |
US5855911A (en) | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
US5844905A (en) | 1996-07-09 | 1998-12-01 | International Business Machines Corporation | Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange |
US6770291B2 (en) | 1996-08-30 | 2004-08-03 | The United States Of America As Represented By The Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
EP0955999B1 (en) | 1996-08-19 | 2001-12-05 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Novel liposome complexes for increased systemic delivery |
JP2001504831A (ja) | 1996-11-21 | 2001-04-10 | プロメガ・コーポレーション | アルキルペプチドアミドおよび適用 |
US5891467A (en) | 1997-01-31 | 1999-04-06 | Depotech Corporation | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
AU6703198A (en) | 1997-03-21 | 1998-10-20 | Brigham And Women's Hospital | Immunotherapeutic ctla-4 binding peptides |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
ES2340745T3 (es) | 1998-12-23 | 2010-06-08 | Pfizer Inc. | Anticuerpos monoclonales humanos contra ctla-4. |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
US6680068B2 (en) | 2000-07-06 | 2004-01-20 | The General Hospital Corporation | Drug delivery formulations and targeting |
WO2002004511A2 (en) | 2000-07-10 | 2002-01-17 | Board Of Regents, The University Of Texas System | CHROMOSOME 3p21.3 GENES ARE TUMOR SUPPRESSORS |
US20040234586A1 (en) | 2001-06-11 | 2004-11-25 | Sylvain Meloche | Compositions and methods for enhancing nucleic acid transfer into cells |
ATE468861T1 (de) | 2001-08-16 | 2010-06-15 | Univ Pennsylvania | Synthese und verwendung von reagenzien für die verbesserte dna-lipofektion und/oder prodrug- und arzneimitteltherapien mit langsamer freisetzung |
ATE485031T1 (de) | 2002-06-28 | 2010-11-15 | Protiva Biotherapeutics Inc | Verfahren und vorrichtung zur herstellung von liposomen |
AU2003279010A1 (en) | 2002-09-28 | 2004-04-19 | Massachusetts Institute Of Technology | Compositions and methods for delivery of short interfering rna and short hairpin rna |
WO2004064731A2 (en) | 2003-01-14 | 2004-08-05 | University Of Washington | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymlplhoid tissues |
KR20060079180A (ko) | 2003-07-02 | 2006-07-05 | 노보 노르디스크 에이/에스 | Nk 세포 활성을 조절하기 위한 조성물 및 방법 |
ES2619171T3 (es) | 2003-07-24 | 2017-06-23 | Innate Pharma S.A. | Métodos y composiciones para aumentar la eficacia de anticuerpos terapéuticos utilizando compuestos para la potenciación de linfocitos NK |
EP1791868B1 (en) | 2004-07-01 | 2011-02-23 | Novo Nordisk A/S | Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use |
JP5855326B2 (ja) | 2005-01-06 | 2016-02-09 | ノヴォ ノルディスク アー/エス | 抗kir組み合わせ治療および方法 |
EP1836225B1 (en) | 2005-01-06 | 2011-11-02 | Novo Nordisk A/S | Kir-binding agents and methods of use thereof |
KR20070111542A (ko) | 2005-03-09 | 2007-11-21 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 암 치료유전자의 종양-특이적, 발현 고효율을 위한 신규한hTMC 프로모터 및 벡터 |
EP1957045A2 (en) | 2005-03-14 | 2008-08-20 | Board of Regents, The University of Texas System | Bioactive fus1 peptides and nanoprticle-polypeptide complexes |
CA2970873C (en) | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
AU2006301163B2 (en) | 2005-10-14 | 2012-02-23 | Innate Pharma | Compositions and methods for treating proliferative disorders |
US20110052570A1 (en) | 2005-10-26 | 2011-03-03 | Children's Medical Center Corporation | Method to prognose response to anti-egfr therapeutics |
AU2007249542B2 (en) | 2006-05-09 | 2009-11-05 | Colgate-Palmolive Company | Oral care regimen |
CN105037549B (zh) | 2007-01-11 | 2018-09-28 | 诺和诺德公司 | 抗-kir抗体、制剂及其应用 |
EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
EP3222634A1 (en) | 2007-06-18 | 2017-09-27 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
US8747847B2 (en) | 2008-02-11 | 2014-06-10 | Curetech Ltd. | Monoclonal antibodies for tumor treatment |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
KR20110074850A (ko) | 2008-08-25 | 2011-07-04 | 앰플리뮨, 인크. | Pd-1 길항제 및 그의 사용 방법 |
US8709411B2 (en) | 2008-12-05 | 2014-04-29 | Novo Nordisk A/S | Combination therapy to enhance NK cell mediated cytotoxicity |
EA201270228A1 (ru) | 2009-07-31 | 2012-09-28 | Медарекс, Инк. | Полноценные человеческие антитела к btla |
CN102666581A (zh) | 2009-08-31 | 2012-09-12 | 艾普利穆恩公司 | 用于抑制移植物排斥的方法和组合物 |
WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
CN103038251B (zh) | 2010-02-19 | 2016-08-17 | Xencor公司 | 新颖ctla4-ig免疫粘附素 |
US8802091B2 (en) | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
EA035033B1 (ru) | 2010-11-22 | 2020-04-20 | Иннейт Фарма Са | Способ лечения гематологического предракового или гематологического ракового заболеваний |
US20120244209A1 (en) | 2011-03-02 | 2012-09-27 | Roth Jack A | Tusc2 therapies |
AU2012260601B2 (en) | 2011-05-25 | 2018-02-01 | Innate Pharma, S.A. | Anti-KIR antibodies for the treatment of inflammatory disorders |
WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
AU2012296613B2 (en) | 2011-08-15 | 2016-05-12 | Amplimmune, Inc. | Anti-B7-H4 antibodies and their uses |
WO2013067492A1 (en) | 2011-11-03 | 2013-05-10 | The Trustees Of The University Of Pennsylvania | Isolated b7-h4 specific compositions and methods of use thereof |
US20130247924A1 (en) | 2012-03-23 | 2013-09-26 | Mark Scatterday | Electronic cigarette having a flexible and soft configuration |
US9731012B2 (en) | 2012-03-30 | 2017-08-15 | President And Fellows Of Harvard College | Laser-actuated therapeutic nanoparticles |
JP2014022858A (ja) | 2012-07-17 | 2014-02-03 | Murata Mfg Co Ltd | 電力増幅器 |
US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
DK3013350T3 (da) | 2013-06-25 | 2020-04-14 | Vaccinex Inc | Anvendelse af semaphorin-4D-hæmmende molekyler i kombination med en immunmodulerende terapi for at hæmme tumorvækst og metastaser |
AU2014296887A1 (en) | 2013-08-02 | 2016-01-28 | Aduro Biotech Holdings, Europe B.V. | Combining CD27 agonists and immune checkpoint inhibition for immune stimulation |
AU2013400609B9 (en) | 2013-09-13 | 2020-03-05 | Beigene Switzerland Gmbh | Anti-PD1 antibodies and their use as therapeutics and diagnostics |
US10350275B2 (en) | 2013-09-21 | 2019-07-16 | Advantagene, Inc. | Methods of cytotoxic gene therapy to treat tumors |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
US20170246298A1 (en) * | 2014-09-24 | 2017-08-31 | Apellis Pharmaceuticals, Inc. | Methods and compositions for cancer treatment and treatment selection |
-
2017
- 2017-10-12 RU RU2019114031A patent/RU2755903C2/ru active
- 2017-10-12 EP EP17861125.7A patent/EP3525809A4/en active Pending
- 2017-10-12 US US16/341,134 patent/US11278592B2/en active Active
- 2017-10-12 CA CA3040458A patent/CA3040458A1/en active Pending
- 2017-10-12 CN CN201780076886.XA patent/CN110072540B/zh active Active
- 2017-10-12 MA MA046542A patent/MA46542A/fr unknown
- 2017-10-12 SG SG11201903283UA patent/SG11201903283UA/en unknown
- 2017-10-12 WO PCT/US2017/056338 patent/WO2018071668A1/en unknown
- 2017-10-12 JP JP2019519701A patent/JP7041136B2/ja active Active
- 2017-10-12 BR BR112019007365A patent/BR112019007365A2/pt unknown
- 2017-10-12 KR KR1020197013556A patent/KR102661905B1/ko active IP Right Grant
- 2017-10-12 AU AU2017342364A patent/AU2017342364B2/en active Active
- 2017-10-12 CN CN202310535801.7A patent/CN116672456A/zh active Pending
-
2019
- 2019-04-11 IL IL265965A patent/IL265965A/en unknown
- 2019-04-12 CL CL2019001002A patent/CL2019001002A1/es unknown
-
2022
- 2022-02-17 US US17/674,800 patent/US20220168388A1/en active Pending
- 2022-03-10 JP JP2022037295A patent/JP2022081616A/ja active Pending
-
2023
- 2023-03-15 AU AU2023201601A patent/AU2023201601A1/en active Pending
-
2024
- 2024-02-22 JP JP2024025307A patent/JP2024057000A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007092944A2 (en) * | 2006-02-08 | 2007-08-16 | Introgen Therapeutics, Inc. | Compositions and methods involving gene therapy and proteasome modulation |
Also Published As
Publication number | Publication date |
---|---|
EP3525809A1 (en) | 2019-08-21 |
JP2022081616A (ja) | 2022-05-31 |
AU2017342364B2 (en) | 2022-12-15 |
BR112019007365A2 (pt) | 2019-07-09 |
CA3040458A1 (en) | 2018-04-19 |
RU2019114031A3 (zh) | 2020-11-13 |
KR102661905B1 (ko) | 2024-04-29 |
JP2024057000A (ja) | 2024-04-23 |
KR20190067216A (ko) | 2019-06-14 |
MA46542A (fr) | 2021-03-31 |
AU2017342364A1 (en) | 2019-05-23 |
IL265965A (en) | 2019-06-30 |
RU2755903C2 (ru) | 2021-09-22 |
WO2018071668A1 (en) | 2018-04-19 |
RU2019114031A (ru) | 2020-11-13 |
SG11201903283UA (en) | 2019-05-30 |
CL2019001002A1 (es) | 2019-11-08 |
CN116672456A (zh) | 2023-09-01 |
JP7041136B2 (ja) | 2022-03-23 |
US11278592B2 (en) | 2022-03-22 |
US20220168388A1 (en) | 2022-06-02 |
US20200038480A1 (en) | 2020-02-06 |
EP3525809A4 (en) | 2020-06-03 |
CN110072540A (zh) | 2019-07-30 |
AU2023201601A1 (en) | 2023-04-13 |
JP2019534268A (ja) | 2019-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2741784B1 (en) | Tusc2 therapies | |
US20220168388A1 (en) | Methods and compositions for tusc2 immunotherapy | |
US20200009203A1 (en) | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases | |
AU2019322487B2 (en) | Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer | |
CN113939309A (zh) | 使用sEphB4-HSA融合蛋白治疗癌症 | |
WO2021113644A1 (en) | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer | |
JP2021506795A (ja) | エキソソーム関連遺伝子編集を用いてがんを処置するための方法および組成物 | |
CN112424219A (zh) | 免疫外排体及其使用方法 | |
US20220226402A1 (en) | Methods and compositions comprising enhanced targeted immune gene therapy for the treatment of cancer | |
WO2022192372A1 (en) | Methods and compositions for tusc2 combination therapy with pdk1 inhibition | |
CN112236130A (zh) | 使用外排体对癌基因的治疗性靶向 | |
US20240042061A1 (en) | Methods and compositions comprising tumor suppressor gene therapy for the inhibition of pathogens | |
US20210100859A1 (en) | Herpes simplex virus (hsv) anticancer therapies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40010583 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant |